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57 ABSTRACT 
The present invention is directed to the synthesis and use of 
novel macrocyclic compounds, based upon a new class of 
expanded porphyrins, termed rubyrins. Disclosed herein is 
the structure and synthesis of a prototypical rubyrin and 
various substituted rubyrin analogues, conjugates and com 
positions. Rubyrin itself is characterized by the presence of 
six pyrrolic subunits contained within a fully aromatic 26 
TC-electron macrocyclic framework and by UV/VIS absorp 
tion bands that are very red-shifted as compared to those of 
other porphyrins or pentapyrrolic expanded porphyrins. The 
rubyrin-type class of compounds is further characterized by 
an ability to undergo facile protonation at the pyrrolic 
nitrogens and, once protonated, by an ability to form com 
plexes with anions such as nucleotide-containing com 
pounds. Rubyrin-based compounds are useful as, for 
example, anion chelators and receptors and as transporters 
for various anionic compounds including antiviral agents. In 
addition to the 26 T-electron target system, the present 
invention concerns other oxidation states bearing the same 
connectivity and the same total number of non-hydrogen 
atoms, and various analogues in which different substituents 
are present at the various meso and/or 3-pyrrolic positions or 
in which furan and/or thiophene moieties replace one or 
more of the six pyrrolic subunits. 
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This application is a divisional of U.S. Ser. No. 08/015, 
208, filed Feb. 9, 1993, now U.S. Pat. No. 5,410,045 which 
is a continuation-in-part of U.S. Ser. No. 07/926,357, filed 
Aug. 4, 1992, now abandoned. The government owns rights 
in the present invention pursuant to NIH grant AI 28845. 
BACKGROUND OF THE INVENTION 
1. Field of the. Invention 
The present invention relates generally to macrocyclic 
expanded porphyrin compounds, and particularly, to the 
novel expanded porphyrin termed rubyrin and to a class of 
rubyrin analogues. Disclosed are rubyrin and rubyrin ana 
logue compounds compositions, and methods of using pro 
tonated rubyrin compounds as anion chelators, receptors and 
transporters. 
2. Description of the Related Art 
In recent years increasing effort has been devoted to the 
preparation of novel "expanded porphyrins', large pyrrole 
containing macrocyclic analogues of the porphyrins (e.g. 
porphine, structure 1, FIG. 1) and a number of such systems 
are now known". However, only a few fully conjugated 
examples have been reported that contain more than four 
pyrrolic subunits, namely the smaragdyrins”, sapphy 
rins, pentaphyrins', hexaphyrins, and superphthalo 
cyanines'. These compounds are represented in their gen 
eralized substituent-free forms as structures 2-6 (FIG. 1). 
To date, there remains relatively little documented infor 
mation concerning the chemistry of the above-mentioned 
expanded porphyrin Systems. Indeed, at present, structural 
information is available only for derivatives of sapphyrin 
(e.g. structure 2)" and pentaphyrin (e.g. structure 3) in the 
all-pyrrole series. Therefore, numerous fundamental ques 
tions concerning these molecules still remain to be 
answered, such as those pertaining to ring size, aromaticity, 
and effective macrocycle stability. The synthesis and struc 
tural characterization of hexapyrrolic macrocycles would be 
a particular advance in this area, allowing the answers to 
such inter-related questions to be elucidated. 
It has long been appreciated that a considerable number of 
ionic (e.g. phosphorylated) nucleotide analogues exhibit 
antiviral activity in cell-free extracts, yet are inactive in vivo 
due to their inability to cross lipophilic cell membranes''. 
For example, the anti-herpetic agent, acyclovir (FIG. 9a, 
9-(2-hydroxyethoxy)methyl-9H-guanine), is typical in that 
it is able to enter the cell only in its uncharged nucleoside 
like form. Upon gaining entry to the cytoplasm it is phos 
phorylated, first by a viral-encoded enzyme, thymidine 
kinase (FIG.9b), and then by relatively nonspecific cellular 
enzymes to produce the active, ionic triphosphate nucle 
otide-like species (FIG. 9c). There it functions both as an 
inhibitor of the viral DNA polymerase and as a chain 
terminator for newly synthesized herpes simplex DNA. 
Many other potential antiviral agents, including, for 
instance, the anti-HIV agent, Xylo-G (FIG. 9d 9-(B-D- 
xylofuranosyl)guanine), on the other hand, are not phospho 
rylated by a viral enzyme and are, therefore, largely or 
completely inactive'. If, however, the active monophos 
phorylated forms of these putative drugs (such as in FIG.9e) 
could be transported into cells, it would be possible to fight 
viral infections with a large battery of otherwise inactive 
materials. If such specific into-cell transport were to be 
achieved, it would therefore greatly augment the treatment 














hepatitis and measles. Given the fact that AIDS is currently 
a major national health problem of frightening proportions, 
and that something so nominally benign as measles still 
claims over 100,000 lives per year world-wide', treatment 
of these diseases would be particularly timely and worth 
while. 
At present, no general set of nucleotide transport agents 
exists. In early work, Tabushi was able to effect adenosine 
nucleotide transport using a lipophilic, diazabicyclooctane 
derived, quaternary amine system. However, this same 
system failed to mediate the transport of guanosine 5'-mono 
phosphate (GMP) or other guanosine-derived nucleotides. 
Since then, considerable effort has been devoted to the 
generalized problem of nucleic acid base ("nucleobase”) 
recognition, and various binding systems have been 
reported. 
Currently known nucleotide binding systems include acy 
clic, macrocyclic, and macrobicyclic polyaza systems'', 
nucleotide-binding bis-intercalands; guanidinium-based 
receptors'', and various rationally designed H-bonding 
receptors'. These latter H-bonding receptors have been 
shown to be effective for the chelation of neutral nucleobase 
and/or nucleoside derived substrates but, without exception, 
have also all proved unsatisfactory for the important task of 
charged nucleotide recognition. Large macrocyclic com 
pounds, particularly macrocyclic compounds larger than 
sapphyrins, which could be relatively easily protonated 
could prove to be useful in anion binding and transport. 
Despite intensive efforts in this field, there is currently no 
synthetic system capable of effecting the recognition and 
through-membrane transport of phosphate-bearing species 
such as anti-viral compounds. Furthermore, there are pres 
ently no rationally designed receptors which are "tunable” 
for the selective complexation of a given nucleobase-derived 
system. 
There is clearly, therefore, a major need for novel drug 
delivery systems to be developed. Compounds which would 
allow negatively-charged (anionic) structures, particularly 
specifically-recognized nucleotides, to be transported across 
naturally lipophilic cellular membranes would represent an 
important scientific and medical advance. The development 
of such anion carriers may also prove to be important in the 
clinical treatment of cystic fibrosis, in that such compounds 
would likely facilitate the out-of-cell diffusion of chloride 
anions. 
SUMMARY OF THE INVENTION 
The present invention addresses these and other short 
comings in the prior art by providing compositions for use 
in specific anion binding and transport. The invention con 
cerns a class of novel expanded porphyrins, or macrocycles, 
termed rubyrin and analogues thereof. Rubyrin and rubyrin 
analogues are able to bind negatively charged substances, 
anions, at near-neutral pH, and have the ability to transport 
anionic compounds across cell membranes. The rubyrin 
macrocyclic compounds of this invention are particularly 
contemplated for use transporting antiviral nucleotide ana 
logues into cells, and in facilitating chloride anion exit from 
cells. They will thus find use in the treatment of a variety of 
viral diseases and also cystic fibrosis. 
Rubyrin and substituted derivatives thereof are red in 
dilute organic solution, hence the use of the trivial name 
"rubyrin' from the Latin rubeus, for this new class of 
expanded porphyrins. Rubyrin itself is a macrocycle which 
can be generally characterized by the presence of six pyr 
5,622,945 
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rolic subunits contained within a fully aromatic 26 TL-elec 
tron macrocyclic framework and by UV/VIS absorption 
bands that are very red-shifted as compared to those of either 
porphyrins or sapphyrins (pentapyrrolic expanded porphy 
rins). 
In a general and overall sense, the novel rubyrin com 
pounds of the present invention include those with structures 
in accordance with the general structures I, II and III, as set 
forth in FIG. 2. In these structures, the substituents A and 
A may be nitrogen, oxygen or sulphur. In general, the 
Substituents R, R2, R3, R R5 and Rs and X1, X2, X3, and 
X may separately and independently be H, alkyl, aryl, 
amino, hydroxyl, alkoxy, carboxy, carboxamide, ester, 
amide, sulfonato, hydroxy substituted alkyl, alkoxyl substi 
tuted alkyl, carboxy substituted alkyl, amino substituted 
alkyl, sulfonato substituted alkyl, ester substituted alkyl, 
amide substituted alkyl, substituted aryl, substituted alkyl, 
substituted ester, substituted ether or substituted amide. 
In certain embodiments, any one of the substituents 
R-R or X-X may be of the formula (CH2)-A- 
(CH2)-B. In this formula, n and m are integers<10 or 
zero; A may be CH, O, S, NH or NR, wherein R, may 
again be any of the groups listed above for R-R, and B will 
be a chosen, or desirable, functional unit. A "chosen func 
tional unit' is used herein to refer to any compound or 
substance which one may desire to conjugate to a rubyrin 
molecule. Compounds based upon nucleobases, such as a 
single nucleobase, modified nucleobase, a nucleobase-type 
anti-viral compound, or an oligo- or polynucleotide; or 
compounds based upon saccharides, such as a sugar, sugar 
derivative or polysaccharide, are particularly contemplated 
for use in conjugating to rubyrin. However, the use of other 
compounds in rubyrin conjugates is also envisioned. Further 
suitable compounds include, for example, metal chelating 
groups; alkylating agents; steroids and steroid derivatives; 
amino acids, peptides and polypeptides; further rubyrin 
molecules, rubyrin derivatives or polymeric rubyrins; other 
macrocyclic compound such as Sapphyrin or texaphyrin, or 
polymers or derivatives thereof, or even a polymeric matrix 
or solid support. 
Rubyrin and analogues thereof may be further character 
ized by the ability to undergo facile protonation at the 
pyrrolic nitrogens and, once protonated, by an ability to 
form complexes with anions. An advantageous functional 
characteristic of rubyrin and analogues thereof is the ability 
to bind anions at near-neutral pH and to transport anions 
across lipophilic structures such as biological membranes. 
Preferred compounds of the present invention therefore have 
the capacity to bind anions and yet the ability to retain 
overall supramolecular charge neutrality. In particular, the 
fact that rubyrins are larger than sapphyrins, the only other 
class of compounds known to display such behavior, makes 
them considerably easier to protonate and thus much more 
effective in the recognition and transport of anions than this 
other class of molecules. This then represents a significant 
advance embodied in the present invention. 
In certain embodiments, the invention concerns a macro 
cyclic rubyrin compound, represented in its generalized 
substituent free form by structure 7 (FIG. 2), a structure in 




It will be understood by those of skill in the art of organic 
chemistry, however, that the present invention is not limited 














included within the context of this disclosure are analogues 
of 7, namely macrocycles based upon structures 8 and 9, 
which have the same overall connectivity and same number 
of non-hydrogen atoms but which differ from the structur 
ally characterized 26 at-electron prototypes by the number of 
total electrons contained within the Tt-electron periphery. For 
example, 28t-electron rubyrin analogues, as described in 
Examples V and VI, fall within the scope of the present 
invention. A particular example of a compound in accor 
dance with structure 8 is structure 19 of FIG. 5, namely 
4,8,13,18,23,27-hexaethyl-3,9,14, 17.22,28-hexamethyl-29, 
30,3132,33,34-hexaazaheptacyclo[24.2.1.1° 17'1'. 
15.1''.1''tetratriaco inta-1,3,5,7,9,11,13,15, 17, 19.21, 
23,25,27-tetradecaene. 
Rubyrin compounds in which two or more of the pyrrolic 
nitrogen atoms have been replaced by oxygen or sulfur are 
also encompassed by the present invention. In this context, 
the oxygen or sulfur atoms are termed "heteroatoms', and 
the resultant rubyrin analogues may be referred to as het 
eroatomic compounds. Rubyrin analogues comprising four 
heteroatoms are exemplified in general by the macrocycle 
structures 20–24 (FIG. 6), which may variously contain two 
or four nitrogen, oxygen or sulphur atoms. The synthesis of 
rubyrin analogues in which two, four, or even six, of the 
nitrogen atoms have been replaced by oxygen or sulfur is 
described in Example X. The condensation of differing 
oxygen- or sulphur-containing units, from any one of a 
variety of readily available starting materials, under the 
rubyrin forming conditions disclosed herein, will result in 
the generation of macrocycles with any desired combination 
of nitrogen, oxygen or sulfur, based on starting materials 
chosen. Macrocycles containing combinations of nitrogen 
with either oxygen or sulphur, or alternatively, oxygen in 
combination with sulphur, such as those represented by 
structures 87, 92, 99 and 104 in reaction schemes P through 
S, are therefore encompassed by the present invention. 
It will also be understood that any of the above rubyrin 
compounds may be either singly or doubly protonated, and 
in certain embodiments, triply or four-fold protonated. 
The rubyrin compounds of the present invention are 
specifically exemplified by those compounds having struc 
tures in accordance with structures 10a, 10b, 17a, 17b, 18a, 
18b and 19, as set forth in FIGS. 3, 4 and 5, respectively, as 
well as by other structures discussed hereinbelow and/or set 
forth in the figures and various reaction schemes presented 
herein. As will be understood by those of skill in the art, the 
present invention also encompasses several other rubyrin 
analogues. For example, different combinations of bipyr 
roles and pyrroles may be employed, such as those set forth 
in FIGS. 11 and 12, both in the first and second condensation 
steps, to yield a variety of different products. In one instance, 
this is exemplified herein by the generation of a rubyrin 
analogue in which four of the 12 possible B-pyrrolic posi 
tions are either unsubstituted or replaced by a range of 
functionalized alkyl groups. The generation of various other 
rubyrin analogues is described throughout the specification, 
such as in Example VII, and represented in various reaction 
schemes, for example, Schemes A through E. A range of 
compounds with a wide variety of alkyl and/or aryl sub 
stituents in the meso and/or 3-pyrrolic positions thus fall 
within the scope of the present invention, as represented by 
exemplary structures 27, 35, 40 and 47. 
Any macrocyclic compound with a structure in accor 
dance with any of structures 7, 8, 9, or 20-24 may be 
prepared in which different substituents are present at the 
various meso and/or f3-pyrrolic positions or in which furan 
and/or thiophene moieties replace one or more of the six 
5,622,945 
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pyrrolic subunits. Such substituents may separately and 
independently include, H, alkyl, aryl, amino, hydroxyl, 
alkoxy, carboxy, carboxamide, ester, amide, sulfonato, 
hydroxy substituted alkyl, alkoxyl substituted alkyl, carboxy 
substituted alkyl, amino substituted alkyl, sulfonato substi 
tuted alkyl, ester substituted alkyl, amide substituted alkyl, 
substituted aryl, substituted alkyl, substituted ester, substi 
tuted ether, or substituted amide groups. 
Examples of functional group manipulation in B-substi 
tuted pyrroles are shown in FIG. 11, and starting pyrroles in 
FIG. 12. Methods for the preparation of such pyrroles will 
be apparent to those of skill in the art and are described in 
various references, for example, Paine (1978); Sessler et 
al. (1991); and Zard & Barton, (1985). Functional 
group manipulation of the B-positions is possible after 
macrocycle formation, or the appropriately substituted pyr 
roles may be used directly, depending upon the particular 
pyrrole to be used. The O-positions may be carboxyl-, ester-, 
formyl-, alkyl-, and/or unsubstituted and may also be 
directly linked to other pyrroles or linked to other pyrroles 
via a methylene bridge. 
The synthetic methodology of the present invention also 
provides for the synthesis of a wide variety of other rubyrin 
derivatives or conjugates, wherein a functionalized rubyrin 
macrocycle is appended to a moiety of desirable chemical 
function. Rubyrin may thus also be conjugated to, for 
example, nucleobases, nucleobase derivatives and oligo- or 
polynucleotides, sugars, sugar derivatives and polysaccha 
rides; metal chelating agents; other rubyrin molecules, 
polynubyrins, sapphyrin or texaphyrin, polymers and solid 
support matrices; amino acids, peptides and polypeptides; 
steroids and steroid derivatives; and alkylating agents. It is 
contemplated that one of skill in the art will be able to 
prepare various rubyrin conjugates, including those listed 
above, without undue experimentation given the readily 
available starting materials and in light of the synthetic 
methodology disclosed in the present application. 
In certain embodiments, rubyrin compounds are contem 
plated which contain the rubyrin macrocycle core for phos 
phate binding and also nucleobase "appendages' for specific 
nucleic acid recognition (FIG. 10). These are referred to as 
rubyrin-nucleobase conjugates, which term is intended to 
include any conjugate formed by the covalent conjugation of 
any rubyrin macrocycle to any nucleobase. The rubyrin 
nucleobase conjugates of the present invention may be of 
either the mono- or di-substituted forms, as represented by 
the general structures IV and V (FIG. 10). A mono-substi 
tuted rubyrin-nucleobase conjugate is a compound in which 
only one position, i.e., only one of the groups R-R, or even 
X-X, is covalently attached to a nucleobase-containing 
compound, whereas di-substituted conjugates have nucleo 
base substitutions at two independent positions. Both mono 
and di-substituted conjugates may comprise one, two, or a 
plurality of nucleobase units, the difference being in the 
point of attachment and not in the number of individual units 
attached to the macrocycle. The synthesis of such conjugates 
is described in Example VIII and specific rubyrin-nucleo 
base conjugates are exemplified in structures 51, 55, 59 and 
63 of reaction schemes F through I. 
The term “nucleobase' as used herein, refers generally to 
any moiety that includes within its structure a purine or 
pyrimidine, a nucleic acid, nucleoside, nucleotide, or any 
derivative of any of these, such as a "protected” nucleobase. 
Thus, the term nucleobase includes adenine, cytosine, gua 
nine, thymidine, uridine, inosine, and the like, bases, nucle 
otides or nucleosides, as well as any base, nucleotide or 













A particular example of a useful nucleobase are the 
so-called antimetabolites that are based upon the purine or 
pyrimidine structure. These structures typically exert their 
biological activity as antimetabolites through competing for 
enzyme sites and thereby inhibiting vital metabolic path 
ways. However, in the context of the present invention, the 
inventors are employing the term "antimetabolite nucleo 
base' quite broadly to refer to any purine or pyrimidine 
based molecule that will effect an anticellular, antiviral, 
antitumor, antiproliferative or antienzymatic effect, regard 
less of the underlying mechanism. Exemplary structures are 
shown in Table 1, and include the antimetabolites FU, AraC, 
AZT, ddI, xylo-GMP, Ara-AMP, PFA and COMDP. 
It is contemplated that rubyrin-nucleobase conjugates will 
have a wide variety of applications, including their use as 
carriers for the delivery of antiviral drugs to a particular 
body or even subcellular locale. In the case of antimetabolite 
nucleobases, it is known that many nucleobase antimetabo 
lites can not be readily employed in therapy due to the fact 
that their charged nature inhibits their uptake by target cells, 
or otherwise inhibits or suppresses their unencumbered 
movement across biological membranes. Typically, this 
shortcoming is due to the presence of charged structures 
such as phosphates, phosphonates, sulfates or sulfonates on 
the nucleobase, which due to their charged nature prevents 
or inhibits their crossing of a biological membrane. It is 
proposed that the rubyrins of the present invention can be 
employed as transport agents for carrying such nucleobases 
across membranes, (whether the nucleobase is directly con 
jugated to the macrocycle or simply complexed with it). This 
point is elaborated in further detail in Sessler et al (1992) 
incorporated herein by reference. 
Generally speaking, in the context of rubyrin-nucleobase 
constructs designed for drug delivery it will usually be the 
case that one will employ only one or two nucleobase 
containing substituents for each rubyrin macrocycle. Ruby 
rin derivatives with a single nucleobase are termed "ditopic 
receptors', whereas those with two nucleobases are termed 
“tritopic receptors'. However, the invention is not limited to 
compounds containing one or two nucleobase units, indeed, 
mono- or di-substituted rubyrin-nucleobase conjugates may 
have any number of nucleobases or nucleobase oligomers or 
polymers attached. The ultimate number of such residues 
that are attached will, of course, depend upon the applica 
tion. One may employ a rubyrin derivative with 10 or so 
bases attached to bind and transport complementary oligo 
or poly-nucleotides. Of course, there is no limitation to the 
particular position(s) within the rubyrin macrocycle to 
which the nucleobase(s) may be attached to create a conju 
gate. 
Further examples of rubyrin derivatives or conjugates 
encompassed by the present invention are rubyrin saccharide 
derivatives, wherein the macrocycle is appended to a sac 
charide-based unit, such as a sugar, Sugar derivative or 
polysaccharide. The synthesis of rubyrin-saccharide com 
pounds is described in Example IX and specific rubyrin 
saccharide conjugates are represented by structures 66, 68, 
76 and 84 in reaction schemes J, K, M and O, respectively. 
A non-exhaustive, exemplary list of sugars which may be 
conjugated to rubyrin in this manner is set forth in Table 2. 
Of course, any sugar or modified sugar may be employed 
including sugars having additional phosphate, methyl or 
amino groups and the like. Moreover, the use of both D- and 
L-forms, as well as the O. and B forms are also contemplated. 
The use of Sugars such as glucose, galactose, galactosamine, 
glucosamine and mannose is particularly contemplated. 
Rubyrin-saccharide conjugates are envisioned to be of use 
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where one would like to control, or otherwise modify, the 
water solubility of the resultant rubyrin-based compound, 
for example, in exploiting its novel properties in connection 
with human or animal applications. 
In still further embodiments, the invention concerns com 
positions which are composed of a rubyrin derivative in 
accordance with any one of the embodiments discussed 
above complexed to a second substance, wherein the second 
substance includes within its structure a negatively charged 
moiety. More particularly, the second substance will include 
a negatively charged component such as a chloride, phos 
phate, phosphonate, sulfate, or sulfonate moiety, of which, 
rubyrin-chloride ion complexes are a particular example. 
In other preferred embodiments, the second substance 
will include a purine or pyrimidine, or an analog of either, 
within its structure. As mentioned above, these nucleobase 
structures include, for example, adenine, cytosine, guanine, 
thymidine, uridine and inosine; various antimetabolic or 
antienzymatic nucleobase compounds; and also oligo or 
polynucleotides such as DNA or RNA. Antimetabolic and 
antienzymatic compounds include those with antitumor, 
anticellular, antiproliferative and antiviral activity, examples 
of which are represented in Table 1. 
In further related embodiments, the invention concerns a 
method for forming a complex between a rubyrin macro 
cycle and a negatively charged second substance, or selected 
agent. The method involves preparing a rubyrin or rubyrin 
analogue or conjugate, such as any one of the rubyrin 
derivatives as described above, and contacting this rubyrin 
or rubyrin derivative with a negatively charged substance or 
selected agent under conditions effective to allow the for 
mation of a complex between the rubyrin macrocycle and 
the negatively charged substance. 
This method is appropriate for binding, or complexing, a 
range of negatively charged substances or selected agents, 
such as for example, chloride ions and other halides, 
pseudohalides such as azide or cyanide anions, and anionic 
clusters such as ferricyanide. The complexing of phosphate 
containing compounds, including, simple alkyl or aryl phos 
phates, nucleotides, oligo- and polynucleotides, such as 
DNA, RNA and anti-sense constructs, and nucleotide ana 
logues is particularly contemplated. Even more preferable, is 
the complexing of antiviral compounds such as phosphonate 
derivatives and simple species such as the pyrophosphate 
derivatives PFA and COMDP; the antiviral agents of FIG. 
9b, e,f,g,h,i, and Table 1, and particularly, acyclovir mono 
phosphate, Xylo-GMP, Ara-AMP. Here, as throughout this 
invention, a key embodiment is the high basicity of the 
rubyrin or pseudo rubyrin core, which allows this class of 
compounds and its derivatives to act as vastly improved 
anion chelators or carriers in comparison to expanded por 
phyrins such as sapphyrins or any other extant system. 
Still further methodological embodiments concern meth 
ods for the cellular transport of a given substance, generally 
a negatively charged substance. This may be employed as a 
means of, for example, successfully introducing a negatively 
charged substance into a cell, or alternatively, as a means of 
facilitating the removal of a negatively charged substance 
from a cell. To achieve this, one would prepare a rubyrin 
macrocycle in accordance with the present invention, con 
tact the macrocycle with the negatively charged substance 
under conditions effective to allow complex formation, and 
then simply contact the cell, either in vitro or in vivo, with 
the macrocycle-bound substance. 
Any one of a variety of negatively charged substances 













organism, in this manner. The delivery of polynucleotides, 
including anti-sense constructs, and nucleotide analogues, 
such as antiviral compounds, is particularly envisioned. One 
example concerns the introduction of a rubyrin-complex 
composition which includes an antiviral antimetabolic or 
antienzymatic compound into a cell suspected of being a 
virally infected target cell. Another example is the introduc 
tion of an antitumor antimetabolic or antienzymatic com 
pound into a cell suspected of being a tumor or proliferating 
cell. 
Of course, it is contemplated that such target cells may be 
located within an animal or human patient, in which case an 
effective amount of the complex, in pharmacologically 
acceptable form, would be administered to the patient. 
Generally speaking, it is contemplated by the inventors that 
useful pharmaceutical compositions of the present invention 
will include the selected rubyrin derivative in a convenient 
amount that is diluted in a pharmacologically or physiologi 
cally acceptable buffer, such as, for example, phosphate 
buffered saline. The route of administration and ultimate 
amount of material that is administered to the patient or 
animal under such circumstances will depend upon the 
intended application and will be apparent to those of skill in 
the art in light of the examples which follow. Preferred 
routes of administration will typically include parenteral or 
topical routes. 
The capacity of rubyrin and analogues thereof to effect 
specific into-cell transport of anti-viral compounds is con 
templated to be of use against a wide variety of debilitating 
diseases such as AIDS, herpes, hepatitis and measles. As a 
mediator of DNA import, rubyrins may conceivably be 
employed in the treatment of any disease in which the 
delivery of an oligonucleotide or DNA fragment would be 
advantageous, such as in supplying a functioning gene, or in 
inhibiting an aberrant gene, for example, by employing an 
antisense DNA construct. As discussed above, the larger 
size, high basicity, and relative ease with which rubyrins 
may be protonated, renders them particularly effective mol 
ecules for use in anion transport. 
Additionally, certain rubyrins with advantageous chloride 
ion transporting properties may be employed as synthetic 
carriers capable of facilitating out-of-cell diffusion of chlo 
ride anions, and are therefore contemplated for use as 
therapeutic agents for the treatment of cystic fibrosis. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Porphyrins and expanded porphyrins (large pyr 
role-containing macrocyclic porphyrin analoguss). Structure 
1, porphine; structure 2, Smaragdyrin; structure 3, sapphyrin; 
structure 4, pentaphyrin, structure 5, hexaphyrin; structure 6, 
superphthalocyanine. Compounds in structures 2-6 are all 
represented in their generalized substituent-free forms. 
FIG. 2. Rubyrin and rubyrin analogues. Structure 7, 
rubyrin (29.30,3132,33,34-hexaazaheptacyclo[24.2.1.1% 
5.17.1%. 16'.1??"tetratriaconta-1,3,5,7(31),8,10,12, 
14,16,18,20,22,24(34).25,27-pentadecaene); structures 8 
and 9, the same overall connectivity and same number of 
non-hydrogen atoms as rubyrin, but different number of total 
electrons contained within the y-electron periphery. Struc 
tures I, II and III represent more general versions of the 
rubyrins of the present invention. In these structures, A and 
A may be nitrogen, oxygen or sulphur. The substituents 
R-R and X-X may be separately and independently H, 
alkyl, aryl, amino, hydroxyl, alkoxy, carboxy, carboxamide, 
ester, amide, sulfonato, hydroxy Substituted alkyl, alkoxyl 
5,622,945 
substituted alkyl, carboxy substituted alkyl, amino substi 
tuted alkyl, Sulfonato substituted alkyl, ester substituted 
alkyl, amide substituted alkyl, substituted aryl, substituted 
alkyl, Substituted ester, substituted ether, substituted amide; 
or may be of the formula (CH2)-A-(CH2)-B. In this 
formula, n and m are integers<10 or Zero; A may be CH, O, 
S, NH or NR, wherein R may again be any of the above 
groups; and B will be a chosen or selected functional group. 
Preferred groups for B are contemplated to be nucleobases, 
modified nucleobases, oligonucleotides, sugars, sugar 
derivatives or polysaccharides; however, other suitable 
groups include, for example, metal chelating groups, alky 
lating agents, steroids, steroid derivatives, amino acids, 
peptides, polypeptide, rubyrin, rubyrin derivative, polymeric 
rubyrin, other macrocyclic compounds such as sapphyrins or 
texaphyrins, polymeric matrices or solid supports. 





rubyrin); structure 10b, the counterpart wherein R=CH 
and R=H. 
FIG. 4. Reaction scheme for the synthesis of structure 17, 
the diprotonated form of 4,8,13,18,23,27-hexaethyl-3,9,14, 
17,22,28-hexamethylrubyrin, also demonstrating structures 
11-16; 7a, 17b, 18a and 18b. 
FIG. 5. Structure 19, the rubyrin-like system, 4,8,13,18, 
23,27-hexacthyl-3,9,14, 17.22,28-hexamethyl-29.30,3132, 
33,34-hexaazaheptacyclo[24.2.1.125.17.10.112.15.16, 1912, 
24)tetra triaconta-1,3,5,7,9,11,13,15, 17,19,21,23,25,27-tet 
radecaene. 
FIG. 6. Structures 20–24, rubyrin analogues employing 
heteroatoms, i.e., variously including nitrogen, oxygen and 
Sulphur atoms. In that these structures are generally based 
upon structures I, II and III, it will be understood that they 
may also include any of the substituents listed above for 
R-R and X-X, namely, H, alkyl, aryl, amino, hydroxyl, 
alkoxy, carboxy, carboxamide, ester, amide, sulfonato, 
hydroxy substituted alkyl, alkoxyl substituted alkyl, carboxy 
substituted alkyl, amino substituted alkyl, sulfonato substi 
tuted alkyl, ester substituted alkyl, amide substituted alkyl, 
Substituted aryl, substituted alkyl, substituted ester, substi 
tuted ether and substituted amide. 
FIG. 7. The UV/VIS absorption spectra of 17b ( ) and 
the diprotonated derivatives of 2,3,7,8,12,13,17, 18-octaeth 
ylporphyrin (recorded in the presence of excess TFA) ( . ) 
and 3,8,12,13,17,22-hexaethyl-2,7,18,23-tetramethylsap 
phyrin (recorded as the dihydrochloride salt) (-) in dilute 
CH2Cl2. 
FIG.8. Molecular structure of 17b showing partial atom 
labeling scheme and the H-bonding interactions of the Cl 
counterions with the macrocycle (dashed lines). Top: View 
perpendicular to the plane through the nitrogen atoms. 
Below: Side view showing the nearly planar conformation 
of the core macrocycle. The macrocycle lies around an 
inversion center. Atoms labeled with a' are related by -x, 1 
y, 1-Z. Thermal ellipsoids are scaled to the 30% probability 
level. H atoms represented as spheres of arbitrary size. The 
disordered atoms and the chloroform molecules are not 
shown. Selected bond distances (A) and angles (): N1 
C1, 1.373(5); N1 C4, 1.394(6); C1 C2, 1437(7); C2 
C3, 1.362(5); C3 C4, 1.429(6); C4 C5, 1.381(5); 
C5 C6, 1.379(6); C6 C7, 1421(5); C7 C8, 1.377(9); 
C8 C9, 1449(8); N2 - C6, 1.383(7); N2 - C9, 1.367(5); 













6.352(7); N1 N2', 5.836(5); N1 N3', 3.078(5); N2 
N2, 7.213(7); N3 - N3'6,354(7); N1 C11, 3.265(4); N2 
C11, 3.158(4); N1 C4 C5, 130.1(4); C3 C4 
C5, 123.4(4); C4 C5 C6, 137.6(5); C5 C6 C7, 
1229(5); C5 C6 N2, 1295(4). 
FIG. 9. Structures of anti-viral and potentially anti-viral 
compounds a, acyclovir (9-(2-hydroxyethoxy)methyl)-9H 
guanine); b, phosphorylated form after viral thymidine 
kinase action; c, active, ionic triphosphate nucleotide-like 
species; d, Xylo-G (9-(B-D-xylofuranosyl)guanine); e, phos 
phorylated form; f&g, anti-HSV and anti-HIV phosphonate 
derivatives; h, the pyrophosphate derivative PFA; and i, the 
pyrophosphate derivative COMDP. 
FIG. 10. Rubyrin nucleobase derivatives. Rubyrin nucleo 
base conjugates may be of the mono- or di-substituted 
forms, as represented by the general structures IV and V. 
Mono-substituted rubyrin-nucleobase conjugates may con 
tain, but are not limited to, a single nuclepbase unit, when 
they are termed ditopic rubyrin receptors. Di-substituted 
rubyrin-nucleobase conjugates containing two nucleobase 
units are termed tritopic rubyrin receptors. In structures IV 
and V, the groups R-R which do not contain a nucleobase 
functional unit, and groups X-X, may be H, alkyl, aryl, 
amino, hydroxyl, alkoxy, carboxy, carboxamide, ester, 
amide, Sulfonato, hydroxy substituted alkyl, alkoxyl substi 
tuted alkyl, carboxy substituted alkyl, amino substituted 
alkyl, Sulfonato Substituted alkyl, ester substituted alkyl, 
amide substituted alkyl, substituted aryl, substituted alkyl, 
Substituted ester, substituted ether and substituted amide. At 
least one of the R groups will be of the formula (CH)- 
A-(CH2), B, wherein A may be CH, O, S, NH or NR, 
and R7 may be any of the groups listed above and B may be 
one or more nucleobases, nucleobase derivatives or pro 
tected nucleobases. Conjugation of a nucleobase to a rubyrin 
derivative to form a mononucleobase rubyrin conjugate may 
be via any of the R or X groups. Conjugation of the two 
separate nucleobases to a rubyrin derivative to form a 
dinucleobase rubyrin conjugate may also be via any two of 
these groups, however, it is contemplated that the creation of 
a symmetrical molecule will generally be preferred. The 
rubyrin nucleobase derivatives may include any purine or 
pyrimidine nucleobase, such as cytosine, guanine, thymi 
dine, adenine, uridine or inosine. Alternatively, they may 
include modified versions of any of these, such as those 
listed in Table 1, or chemically modified nucleobases such as 
"protected” bases including, for example, a protecting group 
on the amino group of the nucleobase, such as, for example, 
9-fluorenylmethylcarbonyl, benzyloxycarbonyl, 
4-methoxyphenacyloxycarbonyl, t-butyloxycarbonyl, 
1-adamantyloxycarbonyl, benzoyl, N-triphenylmethyl, 
N-di-(4-methoxyphenyl) phenylmethyl. 
FIG. 11. Examples of functional group manipulation in 
f-substituted pyrroles as applied to the synthesis of rubyrins 
and rubyrin analogues. 
FIG. 12. Examples of starting pyrroles for use in the 
synthesis of rubyrins and rubyrin analogues. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
Expanded porphyrins' are large pyrrole-containing mac 
rocyclic analogues of porphyrins (e.g. porphine, structure 1, 
FIG. 1), of which a number are known'''. Prior to the 
present invention, only a few fully conjugated examples had 
been reported that contain more than four pyrrolic subunits, 
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these are the smaragdyrins' sapphyrins' pentaphyrins' 
hexaphyrins, and superphthalocyanines', represented in 
their generalized substituent-free forms as structures 2-6 
(FIG. 1). 
For the most part, the chemistry of the above-mentioned 
expanded porphyrin systems has been communicated in only 
the briefest fashion. In fact, at present, structural information 
is available only for derivatives of sapphyrin (e.g. 2)" and 
pentaphyrin (e.g. 3) in the all-pyrrole series. In particular, 
no structurally characterized hexapyrrolic macrocycles have 
previously been reported. Given this paucity of information, 
the inventors considered that the preparation and study of 
new hexapyrrolic systems would be of interest. It was 
reasoned that such studies would generate important infor 
mation with regards to ring size, aromaticity, and effective 
macrocycle stability. 
As mentioned above, it is known that the effectiveness of 
various antiviral compounds, such as nucleotide analogues, 
is limited in vivo due to their inability to traverse lipophilic 
cell membranes'’. In fact, this has rendered many poten 
tial antiviral agents, including, for instance, the anti-HIV 
agent, Xylo-G (FIG. 9d), largely or completely inactive'. A 
major aim of the present study was therefore to provide a 
means of transporting active monophosphorylated forms of 
these putative drugs (such as in FIG.9e) into cells, which 
would allow a wide range of otherwise inactive compounds 
to be used against viral infections. 
Cystic fibrosis (CF) is the most common lethal genetic 
disease in Caucasians, striking about one in 2,500 U.S. 
infants. This disease, which is becoming increasingly well 
understood as the result of the recent identification of the 
responsible gene mutation, is characterized by an inability to 
produce functional chloride anion channel proteins (the 
cystic fibrosis transmembrane regulator or CFTR pro 
tein) and by an inability to effect sufficient chloride and 
fluid excretion from, among others, pulmonary epithelial 
cells. This, in turn, leads to a thick build up of mucous 
deposits in the lungs and to a higher than normal suscepti 
bility towards fatal pulmonary infections. It is these infec 
tions, often of the Pseudomonas aeruginosa type, that are 
generally the causative agents of cystic fibrosis related 
death. 
At present, the established treatment protocols for cystic 
fibrosis involve treating these secondary infections with 
appropriate antibiotics, as well as adjusting diet and remov 
ing by physical means the deleterious build up of mucocili 
ary secretions. Unfortunately, these methods have not 
succeeded in prolonging the median life expectancy of 
cystic fibrosis patients past the age of 25'. Thus, consid 
erable current effort is being devoted to developing treat 
ments that operate by attacking the underlying cause of 
disease. Here, a variety of approaches have been explored. 
These range from attempts at gene therapy (incorporating 
the normal, wild-type cystic fibrosis gene into epithelia 
cells) to the administration of agents that restore electrolyte 
balance either by opening up other non-CFTR dependent 
chloride anion channels or by inhibiting cellular uptake of 
sodium cations. Unfortunately, the viability of this latter 
electrolyte balance restoration approach still remains lim 
ited. 
In common with the problems associated with antiviral 
administration, the existence of a specific, in this case 
chloride-selective, anion carrier could be of prime clinical 
utility in terms of treating a major public health problem. It 
was the inventors aim in conducting the present Study to 














these medically important anion transport problems to be 
addressed. 
In defining these objectives, the biological importance of 
inter-linked phosphate and halide transport was also con 
sidered. Transport of one anionic species, achieved at the 
expense of the other, could confer considerable clinical 
advantage in the case of purely synthetic nucleotide carriers. 
It would allow one to achieve intracellular delivery of an 
antiviral agent without creating a deleterious osmotic imbal 
ance. Generally, for CF treatment, it is contemplated that 
concurrent out-of-cell chloride and sodium ion transport 
would be the most effective trigger for subsequent fluid 
excretion. However, simultaneous into-cell diffusion of, e.g., 
phosphorylated entities could be used to overcome problems 
associated with out-of-cell chloride anion transport in the 
case of unfavorable chloride anion concentration gradients. 
Despite the previous preparation of several halide-binding 
receptors, none of these may be used as clinical chloride 
anion transporters. For instance, ammonium bicycles bind 
chloride anions with more specificity than bromide and 
iodide', but only at low pH and with very low affinity 
constants. Cryptand cations were found to bind halide 
anions with high affinity and selectivity, and receptors with 
near-exclusive halide specificities have been reported'. 
Unfortunately, these systems suffer from a serious drawback 
as far as anion transport is concerned: They rely on a high 
net positive charge to effect the coordination of a single 
anion. As a result, the supramolecular anion-to-receptor 
complex formed upon anion binding is still highly charged 
and relatively insoluble in organic media. Thus, through 
membrane transport is only achieved if a large, organic 
soluble "helper anion' is added to the halide-bearing trans 
port medium'. 
This same problem of excess charge effects all the other 
known polyammonium halide anion receptors and all halide 
anion chelands of the polyguanidinium type and pyridinium 
based cyclophane class'. Such considerations of charge are 
of lesser concern in the case of the newer metal- and 
metalloid-derived anion receptors''. In this instance, 
however, questions of heavy metal toxicity cloud consider 
ations of possible clinical utility. Thus, the need for good, 
neutralizing chloride anion carriers remains. 
Regarding nucleoside transport, in preliminary work, the 
present inventors employed triisopropylsilyl (TIPS) substi 
tuted (phosphate-free) nucleosides. It was found that effi 
cient and selective through-membrane transport of non 
charged nucleoside analogues could be achieved by using 
the complementary TIPS derivatives as carriers'. Not sur 
prisingly, however, these same TIPS derivatives proved 
completely ineffective as transport agents for the analogous 
phosphate-containing nucleotide derivatives. Thus, whilst 
confirming the viability of a base-pairing approach to selec 
tive nucleotide recognition, this work served to highlight 
further the need for an organic soluble, neutralizing, phos 
phate binding group. 
In this light, the inventors reasoned that ditopic receptors 
capable of recognizing both the anionic phosphate and the 
neutral portions of nucleotide derivatives, such as the purine 
or pyrimidine moieties, may be particularly advantageous in 
the transport of anti-viral compounds. To synthesize such 
compounds, the inventors realized that they had to consider 
the independent development of molecular recognition strat 
egies for the complexation of two very different kinds of 
substrates (charged anionic and neutral nucleobase) and then 
the subsequent co-combination so as to provide a single 
receptor bearing both kinds of binding subunits. Further and 
5,622,945 
13 
significant problems to be overcome were those associated 
with creating a molecule which has the capacity to bind 
anions and yet the ability to retain overall supramolecular 
charge neutrality. 
In initial studies using expanded porphyrins, the inventors 
determined sapphyrin to be ineffective as a phosphate com 
pound transporter, but pentaphyrin to be capable of trans 
porting GMP at pH 6. Unfortunately, not only was this 
process found to be slow, but also extensively inhibited by 
the addition of chloride anion. In addition, sapphyrin and 
anthraphyrin' were found to be capable of halide anion 
transport, but only in those pH regimes where they remain 
monoprotonated. Also, in both cases the anion that was less 
well bound was found to be transported at the greatest rate 
(i.e. chloride by sapphyrin and fluoride by anthraphyrin)''“ 
b. 
The search for an anion-binding compound with the 
ability to retain overall supramolecular charge neutrality, led 
the inventors to synthesize and characterize a novel class of 
hexapyrrolic expanded porphyrins, represented by structure 
7 (FIG. 2), and substituted derivatives thereof. Structure 7 
corresponds to the macrocyclic system 29.30,3132,33,34 
hexaazaheptacyclo[24.2.1.12.17.1%.19.1°tet 
ratriaconta-1,3,5,7(31),8,10,12,14,16,18,2022,24(34).25, 
27-pentadecaene (FIG. 2)'. Also contemplated by the 
invention are macrocyclic analogues of structure 7, such as 
8 and 9, which have the same overall connectivity and same 
number of non-hydrogen atoms but which differ from the 
structurally characterized 26 T-electron prototypes by the 
number of total electrons contained within the TL-electron 
periphery. 
Substituted derivatives of compound 7 are red in dilute 
organic solution, and the trivial name "rubyrin' (from the 
Latin rubeus) has therefore been assigned to this new class 
of expanded porphyrins. It will be this trivial nomenclature 
that is used throughout the present application. Thus, for 
instance, 4,8,13,18,23,27-hexaethyl-3,9,14, 17,22,28-hex 
amethyl-29,30,3132, 33,34-hexaazaheptacyclo[24.2.1 12, 
5.17.10.112.16°. 12' tetratriaconta-1,3,5,7(31),8,10,12, 
14,16,18,2022,24(34),25,27-pentadecaene (structure 10a, 
FIG. 3), is named as 4,8,13,18,23,27-hexaethyl-3,9,14, 17, 
22,28-hexamethylrubyrin. 
The rubyrin and rubyrin analogues of the present inven 
tion are characterized by the capacity to bind anions and yet 
the ability to retain overall supramolecular charge neutrality. 
A particular advantage to rubyrin molecules is their large 
size. This property renders rubyrins easier to protonate than 
other macrocycles and makes them considerably more effec 
tive at anion recognition and transport than any other 
classes, including the sapphyrins. The increased basicity of 
rubyrin relative to sapphyrin is thus of considerable impor 
tance and represents a significant advance relative to the 
existing art. 
The synthesis of the diprotonated form of 4,8,13,18,23, 
27-hexaethyl-3,9,14, 17,22,28-hexamethylrubyrin, structure 
17, contains two key steps. The first involves the acid 
catalyzed condensation between the bis-O-free bipyrrole 
11' and the acetoxy activated pyrrole 12', to give the 
protected tetrapyrrolic derivative 13. Standard near quanti 
tative debenzylation then gave the diacid 14, which was used 
directly in an acid-catalyzed (4)+(2) MacDonald-type' oxi 
dative condensation with the readily available' diformyl 
bipyrrole, 15. The second step, condensation and air oxida 
tion, ultimately provides the diprotonated rubyrin derivative 
17a. Washing either the purified ditosylate salt 17a, or the 














then produced the more crystalline dihydrochloride deriva 
tive 17b. Carrying out a similar sequence starting with 
diformylbipyrrole 16” gave in analogy salts 18a and 18b in 
similar good yield. w 
Compounds 10a and 10b are synthesized from com 
pounds 17 and 18. In both cases, careful neutralization of 
dichloromethane solutions, achieved by washing with aque 
ous sodium bicarbonate, was found to give rise to the 
neutral, free-base forms, corresponding to structures 10a and 
10b (FIG. 3) in the case of salts 17 and 18, respectively. 
Additionally, several other rubyrin analogues are contem 
plated by the present invention. Different combinations of 
bipyrroles and pyrroles, for example see FIGS. 11 and 12, 
may be employed both in the first and second condensation 
steps to yield a variety of different macrocyclic products. 
The generation of further rubyrin analoques is particularly 
described in Example VII, and represented in reaction 
schemes A through E. A range of compounds with a wide 
variety of alkyl and/or aryl substituents in the meso and/or 
3-pyrrolic positions, as exemplified by structures 27, 35, 40 
and 47, thus fall within the scope of the present invention. 
Furthermore, rubyrin analogues employing heteroatoms 
are also within the scope of the present invention. In 
particular, different combinations of oxygen and sulphur 
atoms, either alone, in combination with nitrogen, or in 
combination together, are contemplated. The synthesis of 
rubyrin analogues in which two, four, or even six, of the 
nitrogen atoms have been replaced by oxygen or sulfur is 
described in Example X, and compounds in accordance with 
those represented by structures 20-24 in FIG. 6 and struc 
tures 87, 92, 99 and 104 in reaction scheme P through 
reaction scheme S, are therefore encompassed by the present 
invention. 
The inventors contemplate that rubyrin itself and the 
unconjugated rubyrin analogues of the present invention will 
be of use as drug delivery agents. It is contemplated that they 
will find utility in mediating the cross-membrane transport 
of negatively charged compounds or molecules, including 
halides, pseudohalides, such as azide or cyanide anions, or 
anionic clusters such as ferricyanide. The anion carrying 
properties of rubyrins make them ideal candidates for the 
development of synthetic carriers capable of facilitating 
out-of-cell diffusion of chloride anions, and hence for use as 
therapeutic agents for the treatment of cystic fibrosis. 
Importantly, rubyrin and analogues thereof are contem 
plated for transporting phosphate-containing compounds 
into cells. Phosphate-containing compounds which may be 
transported in this manner include, for example, simple alkyl 
or aryl phosphate, nucleotides such as AMP or GMP, oli 
gonucleotides and DNA or RNA, including anti-sense DNA 
or RNA constructs, and more particularly, antiviral com 
pounds such as those depicted in FIG. 9 (b.e.f,g,hi), Table 





















Any one of a variety of antiviral agents may be delivered 
to a cell using rubyrin or a rubyrin analogue in accordance 
herewith. These agents include, for example, the anti-HSV 
and anti-HIV agents acyclovir monophosphate, Xylo-GMP, 
Ara-AMP, and/or phosphonate derivatives that also have 
documented anti-HSV and anti-HIV activity in vitro' 
(e.g. FIG. 9f and 9g), and simple species such as the 
pyrophosphate derivatives PFA (FIG. 9h) and COMDP 
(FIG. 9i) that have demonstrated anti-HIV reverse tran 
scriptase activity in cell-free media'. 
As mentioned above, the large size, increased basicity and 
ease of protonation of rubyrins makes this class of macro 
cycles considerably more effective at the recognition and 
transport of anions than other classes of molecules. The 
capacity of rubyrin, and analogues thereof, to effect specific 
into-cell transport of anti-viral compounds is contemplated 
to be of advantageous use against a wide variety of debili 
tating diseases, including, for example, herpes, hepatitis, 
measles, and AIDS. Such diseases are of major medical and 
economic importance with AIDS being an international 
health problem and even measles claiming over 100,000 
lives per year world-wide'. 
Furthermore, the inventors reasoned that the rubyrin com 
pounds of the present invention may be rendered even more 
useful as nucleotide transporters if one or more nucleobase 
recognition units were to be "appended' directly onto the 
phosphate-chelating macrocyclic core. This would impart a 
further degree of nucleotide specificity to binding and trans 
port reactions. Accordingly, rubyrin-nucleobase conjugates 
which have been derivatized by the addition of one or more 
nucleobase compounds, as represented by the generalized 
structures IV and V (FIG. 10), form an important aspect of 
the present invention. Rubyrin derivatives with one nucleo 
base per rubyrin molecule are referred to as ditopic recep 
tors, whereas those doubly-functionalized rubyrin deriva 
tives with 2 nucleobases per molecule are termed tritopic 
receptors. 
Rubyrin mononucleobase derivatives may include any of 
the naturally-occurring purine or pyrimidine nucleobases, 
namely, cytosine, guanine, thymidine, adenine, uridine or 
inosine. Equally, they may include modified versions of any 
of these, such as the heterocyclic components of those 
nucleoside/nucleotide analogues listed in Table 1. Also 
included within the invention are the rubyrin mononucleo 
base derivatives including chemically modified nucleobase 
such as "protected' bases. Protecting groups are used to 
protect reactive groups, such as amino and carboxyl groups, 
from inappropriate chemical reactions. Rubyrin-nucleobase 
conjugates with protected bases include, for example, con 
jugates wherein one or more base has a protecting group, 
such as 9-fluorenylmethylcarbonyl, benzyloxycarbonyl, 
4-methoxyphenacyloxycarbonyl, t-butyloxycarbonyl, 
1-adamantyloxycarbonyl, benzoyl, N-triphenylmethyl or 
N-di-(4-methoxyphenyl)phenylmethyl on the amino group 
of the nucleobase. 
The present inventors contemplate many different chemi 
cal means by which to connect nucleobases to rubyrin 
macrocycles. Various spacers may be used for the connec 














terminal amino, or hydroxy function, which allow formation 
of amide and ester bond for the connection of the rubyrin 
and nucleobase units. This bridge may also be modified, e.g., 
by the reduction of the amide bond to give the amine 
function. Specific examples of the synthesis of rubyrin 
nucleobase conjugates are described in Example VIII and 
the resultant compounds are represented by Structures 51, 
55, 59 and 63 of reaction schemes F through I. 
Rubyrin nucleobase conjugates would be useful as anti 
viral adjuvants, capable of binding and solubilizing nucle 
otides and of effecting their selective through-membrane 
transport at or near physiologic pH. Rubyrin nucleobase 
conjugates with appended oligonucleotides are also contem 
plated by the present invention, and would be of use in 
binding and transporting oligo- or polynucleotides, includ 
ing antisense constructs, into cells. As a mediator of DNA 
import, rubyrins may conceivably be employed in the treat 
ment of any disease in which the delivery of an oligonucle 
otide or DNA fragment would be advantageous, such as in 
supplying a functioning gene, or in inhibiting an aberrant 
gene, for example, by employing an antisense DNA con 
Struct. 
Another class of rubyrin derivatives or conjugates con 
templated by the present inventors are the rubyrin saccharide 
derivatives which comprise a rubyrin macrocycle conju 
gated to a sugar, Sugar derivative or polysaccharide. The 
synthesis of rubyrin-saccharide compounds, as represented 
by structures 66, 68, 76 and 84 in reaction schemes J, K, M 
and O, respectively, is described in Example IX. It will be 
understood that any one of a variety of individual sugar 
units, such as those set forth in Table 2, or polymers thereof, 
may be conjugated to rubyrin in accordance herewith. Table 
2 is intended to include modified versions of the sugar units, 
such as sugars having additional phosphate, methyl or amino 
groups and the like, and also includes D- and L-isomers and 
o, and f forms. 
TABLE 2 
















In addition to the rubyrin analogues described above and 
the nucleobase and saccharide conjugates, it will be appre 
ciated that a variety of other substituents, of desirable 
chemical function, may be appended to a functionalized 
rubyrin moiety to create a rubyrin-based conjugate. The 
present inventors contemplate the synthesis of rubyrin con 
jugates including, for example: metal chelator moieties such 
as EDTA, EGTA, 1,10-phenanthralene, DTPA, DOTA, 
crown ether, azacrown, catecholate and ethylene diamine; 
alkylating agents such as ethylene diamine, epoxide and 
bromoacetamide; steroids and steroid derivatives; amino 
acids, peptides and polypeptides; other rubyrins, rubyrin 
derivatives, polymeric rubyrin, or other macrocyclic com 
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pounds such as sapphyrins, texaphyrins or derivatives 
thereof; and polymeric matrices or solid supports such as 
polymers, glasses, agarose, polyacrylamide, controlled pore 
glass, silica gel, polystyrene and Sepharose. 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the spirit and scope of the invention. 
EXAMPLE I 
SYNTHESIS OF RUBYRINSTRUCTURES 17a 
and 17b 
The synthesis of the diprotonated form of 4,8,13,18,23, 
27-hexaethyl-3,9,14, 17.22,28-hexamethylrubyrin, structure 
17, is shown in FIG. 4. It contains two key steps. The first 
involves the acid catalyzed condensation between the bis 
o-free bipyrrole 11'a and the acetoxy activated pyrrole 
12.'. This reaction, which was carried out in analogy to 
earlier syntheses of symmetric tripyrranes', gave the pro 
tected tetrapyrrolic derivative 13 in approximately 66% 
yield. 
In more detail, compounds 11 (3.72 g, 17.2 mmol) and 12 
(10.9 g, 34.5 mmol) were combined in around bottom flask 
with absolute isopropyl alcohol (140 ml) and the resulting 
mixture heated at 80 C. to effect complete dissolution. 
p-Toluenesulfonic acid monohydrate (30 mg) was then 
added and the resulting green solution heated at reflux for 10 
hours under nitrogen. The resulting suspension was then 
cooled to room temperature and placed in a refrigerator for 
one hour. Filtration, washing with cold ethanol, and drying 
in vacuo then afforded compound 13 as a fine, off-white 
powder (8.24g, 66%), which could be further purified by 
recrystallization from CHCl2/MeOH. m.p.-163–166° C.; 
H NMR (300 MHz, CDC1): 80.83 (t, 6H, CH,CH), 1.10 
(t, 6H, CHCH), 2.02 (s, 10H, CH and CHCH), 2.12 (s, 
6H, CH), 2.46 (m, 4H, CHCH), 3.70 (bs, 6H, pyrrole 
CH, and CHPh), 4.55 (bs, 2H, CHPh), 6.85 (m, 4H, 
aromatic), 7.21 (m, 6H, aromatic), 9.89 (bs, 2H, NH), 10.98 
(bs, 2H, NH); C NMR (75.5 MHz, CDC1): 8=11.20, 
11.30, 15.21, 15.61, 16.86, 18.20, 22.34, 65.91, 113.97, 
117.12, 120.76, 121.29, 123.36, 123.51, 126.53, 126.88, 
127.64, 127.82, 133.80, 135.97, 164.48; HRMS (CI): m/z 
726.4142 (M) calcd for CHNO 726.4145 (+0.0003). 
Standard near quantitative debenzylation of 13 then gave 
the diacid 14. This was achieved by dissolving the dibenzyl 
ester 13 (0.24 g, 0.33 mmol) in dry THF (100 ml) and 
subjecting to hydrogenation over 10% palladium-charcoal 
(40 mg) at 1 atm H. The catalyst was then separated by 
filtration, the solvent reduced in volume on a rotary evapo 
rator, and the product precipitated by trituration with hex 
anes. The pale blue precipitate was collected by filtration, 
dried in vacuo (to yield 0.16 g (90%) of 18). 
The diacid, 14, was used directly, without delay, in the 
next step, the synthesis of 17a. This reaction is an acid 
catalyzed (4)+(2) MacDonald-type' oxidative condensa 
tion with the readily available' diformylbipyrrole, 15. This 














taken together represent the second critical step in the 
overall synthetic sequence, then provide, following work-up 
and chromatographic purification, the diprotonated rubyrin 
derivative, 17a in roughly 20% yield. Washing either this 
purified ditosylate salt or the crude reaction mixture with 
aqueous 10% hydrochloric acid then produced the more 
crystalline dihydrochloride derivative, 17b in yields of 63% 
(based on 17a) and 40% (based on 14), respectively. 
In more detail, to create 17a, 17b, and 19, compounds 15 
(136 mg, 0.5 mmol) and 14 (273 mg, 0.5 mmol) were 
dissolved with warming in 1.0 L of absolute ethanol, the 
mixture allowed to cool to room temperature and 2.0 g of 
p-toluenesulfonic acid monohydrate added all at once. Oxy 
gen was then bubbled through the stirred mixture for 18 
hours. The ethanol was then removed on a rotary evaporator 
and the dark purple residue taken up in CHCl and purified 
by column chromatography (Merck type 60 (230-400 mesh) 
Silica gel) using first CHCl and then CHCl/MeOH(98/2) 
as the eluents. Collection of the dark red fraction and 
removal of the solvent gave 105 mg (20%) of 17a which 
could be purified further by recrystallizing from CHCl/ 
hexanes. Collection of the violet fraction also yielded small 
(s.10% yield) amounts of 19. 
Dissolving compound 17a in dichloromethane and wash 
ing with 10% HCl for 2 hours at room temperature then 
afforded, after work up, product 17b in ca. 63% yield. This 
same material could also be obtained in roughly 40% net 
yield by treating the crude condensation product (from 14 
and 15) with 10% HCl prior to work up and chromatogra 
phy. Single crystals of 17b were obtained by vapor diffusion 
recrystallization from CHCl/pentane. 
For 17a: decomp. above 220° C.; H NMR (300 MHz, 
CDCl3): 8-4.14 (s, 2H, NH), -3.68 (s, 4H, NH), 1.50 (s, 
6H, PhCH), 1.90 (d, J-7 HZ, 4H, phenyl H), 2.30 (m, 
18H, CHCH), 3.90 (s, 12H, CH4), 4.10 (m, 8H, CHCH), 
4.30 (s, 6H, CH), 4.70 (q, 4H, CH2CH), 4.90 (d, J-7 Hz, 
4H, phenyl H), 11.18 (m, 4H, meso-H); HRMS (FAB): m/z 
694.4707 (M-2TsO), calcd for CHN 694.4723 
(+0.0016). 
For 17b; decomp. above 230° C.; H NMR (300 MHz, 
CDC1): 8–5.30 (s, 2H, NH), -4.97 (s, 4H, NH), 2.09 (m, 
12H, CHCH), 2.34 (t, J-7 Hz, 6H, CHCH), 4,06 (s, 
12H, CH), 4.40 (s, 6H, CH), 4.43 (m, 8H, CHCH), 4.82 
(q, J–7 Hz, 4H, CHCH), 11.58 (s, 2H, meso-H) 11.60 
(s, 2H, meso-H); C NMR (75.5 MHz, CDC1): 8=12.98, 
15.73, 17.50, 17.99, 21.05, 21.29, 92.74, 92.88, 126.47, 
127.30, 129,03, 129.65, 130.73, 136.38, 139.32, 143.31; 
UVIVIS (CH,Cl): (nm) (e)=505 (302,000), 711 (11, 
000), 791 (15,500), 850 (38,000); HRMS (FAB): m/z. 
694.4660 (M*-Cl), calcd for CHN 694.4723 
(+0.0063). 
For 23: "H NMR (300 MHz, CDC1): 8-098 (m, 9H, 
CHCH), 1.09 (m, 9H, CHCH), 2.06 (m, 18H, CH), 2.37 
(m, 6H, CHCH), 2.57 (m, 6H, CHCH), 6.78 (m, 4H, 
“meso'-H), 11.85 (s, 1H, NH), 12.32 (s, 1H, NH), 12.51 (s, 
1H, NH), 12.60 (s, 1H, NH), 12.62 (s, 1H, NH), 12.74 (s, 
1H, NH); MS (FAB): m/z 696 (M*--1,4%), 695 (M,5%), 
307 (22%), 154 (100%); UV/VIS (CH,Cl): =538 nm. 
EXAMPLE II 
SYNTHESIS OF RUBYRIN STRUCTURES 8a. 
and 18b 
Employing the same rubyrin synthetic methodology as 
described in Example I, but substituting the starting com 
pounds for different starting materials allows a wide range of 
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other rubyrin analogues to be prepared. For example, start 
ing with diformyl bipyrrole 16' and performing the syn 
thesis in the same manner as described above, gave in 
analogy salts 18a and 18b in similar good yield. From 
condensation of 14 (1.1 g, 2 mmol) and 16 (0.545 g, 2 
mmol), 220 mg of compound 18a was obtained (16%). 
H NMR (300 MHz, CDC1): 8–5.66 (s, 4H, NH), -540 
(s, 2H, NH), 1.75 (t, J–7, 6H, CHCHCH), 2.13 (t, 
J–7, 6H, CHCH), 2.36 (t, J–7, 6H, CHCH), 3.06 
(m, 4H, CH2CH2CH), 4.24 (s, 6H, CH), 4.51 (s, 6H, CH), 
4.77 (q, J-7, 4H, CH2CH3), 5.06 (q, J–7, 4H, 
CHCH), 11.17 (s, 2H, “meso'-H), 12.00 (s, 2H, “meso'- 
H), 12.29 (s. 2H, b-H); MS (FAB): m/z 694 (M*-2TsO); 
UV/VIS (CH,Cl) =501 nm. 
EXAMPLE III 
CHARACTERIZATION OF RUBYRIN 




Formally, rubyrin 10 and its derivatives may be consid 
ered as 26 T-electron annulenes. Thus, the diprotonated salts 
17 and 18 were expected to be aromatic. The available 
spectroscopic data is consistent with this aromatic formula 
tion. For instance, low-field meso-like methine signals and 
high-field internal NH resonances were observed in the H 
NMR spectra as would be expected for a large aromatic 
expanded porphyrin system. In the specific case of 17b in 
CDCl3 these signals were observed at 11.58 and 11.60 ppm 
(in a 1:1) ratio, and at -4.97 and -5.30 ppm (in a 2:1 ratio), 
respectively, values which compare closely to those 
observed for the dihydrochloride salt of 3,8,12,13,17,22 
hexaethyl-2,7,18,23-tetramethylsapphyrin H.Sap” mea 
sured under the same experimental conditions'. 
Additionally, both 17 and 18 display Soret-like and 
Q-type transitions in their optical spectra, which, as would 
be expected for a large aromatic expanded porphyrin, are 
considerably red-shifted as compared to those of smaller 
porphyrin-like systems. In fact, relative to H.Sap” and 
H.OEP' (the diprotonated derivative of 2,3,7,8,12,13,17, 
18-octaethylporphyrin) measured under similar experimen 
tal conditions, the Sorer band of 17b is shifted by ca. 50 and 
100 nm, respectively (c.f. FIG. 7). In the case of the lowest 
energy Q-type band, the corresponding shifts are on the 
order of 180 and 270 nm, respectively. 
Further evidence for the aromatic nature of rubyrin was 
obtained from the X-ray diffraction structure of 17b. The 
experimental details are as follows: (CH5NH2)”(CI 
)(CHCl); triclinic, P1 (No. 2), Z=1 in a cell of dimen 
sions: a-10.196(8), b=11.141 (8), c=13.476(9) A, 
o=67.18(5), B=72.97(6), Y=68.56(6), V=1293(2) A, p= 
1.29 g cm (173K), F(000)=526. Data collected at 173K on 
a Nicolet R3 diffractometer, graphite monochromatized Mo 
radiation (A=0.7107 A) using the Q-scan technique out to 
50° in 20; 4573 unique reflections, 2871 with F.s3o(F) 
The structure was solved by direct methods and refined by 
full-matrix least-squares (SHELXTL-Plus, Nicolet XRD, 
Madison, Wis., USA) with anisotropic thermal parameters 
for the non-hydrogen atoms. Hydrogen atoms on C18, C19, 
C19A, C20, C21, C22, C22A and C23 were idealized (C-H 
0.96A) while all others were taken from a AF map. All were 
refined isotropically. The complex lies around an inversion 
center at 0,1/2, 1/2 resulting in the occupational disorder of 
the ethyl and methyl groups of the pyrrole ring containing 
N2. The Cl ions are H-bonded to the pyrrolic hydrogens 











R=0.0678, goodness of fit=2.284 for 361 parameters. The 
minimum and maximum peaks in the final AF map were 
-0.30, 0.38 e A respectively 
As illustrated in FIG. 8, X-ray diffraction studies revealed 
structure 17 to have a near planar conformation for the core 
macrocycle that is only slightly waffled by virtue of inter 
actions with the hydrogen-bound chloride counter anions 
(the maximum deviation (C2) of the C and N macrocycle 
atoms from the mean plane is 0.509(4) A). In fact, this lack 
of distortion is reminiscent of that seen in the X-ray structure 
of IHOEP' (Ref.23) and several recently-reported dipro 
tonated bisvinylogous expanded porphyrins'', suggest 
ing that significant through-cycle TC-electron conjugation 
pertains in 17b. Consistent with this conclusion is the finding 
that the average carbon-carbon and carbon-nitrogen bond 
distances within the formal 26 T-electron periphery (1.394 A 
and 1.375 A, respectively) are close in value to those 
observed in the corresponding diprotonated OEP structure 
(1.390 A and 1.375 A, respectively)'. 
Interestingly, however, the inter-pyrrole angles about the 
bridging methines (137.0° and 137.6°) are considerably 
greater than those found in protonated porphyrins (wherein 
the in-core angles are roughly 127)’. Thus, the expanded 
porphyrin 17b displays an inner core that is more open than 
might perhaps be expected for what may formally be con 
sidered as two directly appended "three-quarter porphyrins' 
linked via two sets of bipyrrole-defining bonds. Nonetheless, 
it is clear that from a structural point of view, compound 17b 
displays all that is expected of an aromatic system. 
EXAMPLE IV 
SYNTHESIS OF RUBYRIN STRUCTURES Oa 
and Ob 




27-pentadecaene (herein termed 4,8,13,18,23,27-hexaethyl 
3,9,14, 17.22,28-hexamethylrubyrin) was achieved as 
described below. 
To synthesize compounds with structures 10a and 10b, the 
Synthesis of compounds 17 and 18 was first conducted, as 
described above in Example III. In both cases, careful 
neutralization of dichloromethane solutions, achieved by 
washing with aqueous sodium bicarbonate, was found to 
give rise to the neutral, free-base forms, corresponding to 
structures 10a and 10b (FIG. 3) in the case of salts 17 and 
18, respectively. 
Specifically, this neutralization is carried out by dissolv 
ing salt 17 or 18 in CHCl in a one-neck round bottomed 
flask and adding Saturated aqueous NaHCO. The two-layer 
mixture is then stirred via a magnetic stirring apparatus for 
two hours. Separating the organic layer from the aqueous 
layer, and washing the organic layer with de-ionized water 
in the same fashion described above, drying the organic 
layer over anhydrous sodium sulfate and removing the 
Solvent on a rotary evaporator affords the neutral, free-base 
rubyrin analogue 1.0a or 10b. 
Interestingly, the free-base form of 10b was generally 
found to be more stable. However, in both cases, the 
free-base form proved rather unstable. Thus, as described 
herein, full characterization was effected using the diproto 




SYNTHESIS OF RUBYRIN ANALOGUE 
STRUCTURE 19 
In addition to those described above, several other prod 
ucts were obtained in the course of the above condensations. 
In the case of primary product 17a, an effort was made to 
characterize these materials and two such minor products 
were thus identified. The first of these was found to be a 
Sapphyrin derivative, namely 3,7,12,18,22-pentaethyl-2,8, 
13,1723-pentamethylsapphyrin. 
The second was a partially reduced, rubyrin-like system, 
4,8,13,18,23,27-hexaethyl-3,9,14, 17.22,28-hexamethyl-29, 
30.31,32, 33,34-hexaazaheptacyclo[24.2.1.1%. 1''.1% 
15.1.1''tetratriaconta-1,3,5,7,9,11,13,15, 17,19,21, 
23,25,27-tetradecaene (structure 19, FIG. 5). This 
compound (structure 19) was received as a byproduct of the 
reaction sequence to produce compound 17a. It has the same 
connectivity but is of different oxidation state. Nonetheless, 
this material appeared to be stable to the reaction conditions. 
Still, however, it could be converted to 17b in near quanti 
tative yield by treating with DDQ in the presence of acetic 
acid and then washing with 10% HC. Thus, at the present 
time, it is not clear whether compound 19 itself (as opposed 
to some other reduced rubyrin species) functions as the 
actual intermediate under the present condensation condi 
tions. 
In any case, this well characterized product, compound 
19, which is bright violet in color, stands as a specific 
embodiment of compounds of the general class represented 
by structure 8 (FIG. 2). Its existence and isolation thus 
stands as evidence inter alia that compounds with the same 
connectivity and total non-hydrogen atom count as rubyrin, 
as exemplified by structure 8, can be prepared according to 
the methods of the present invention. 
EXAMPLE VI 
SYNTHESIS OF RUBYRN ANALOGUES 
REPRESENTED BY STRUCTURE 9 
In addition to those compounds, such as 19, represented 
by structure 8 (FIG. 2), compounds based upon structure 9 
will also have the same connectivity and total non-hydrogen 
atom count as rubyrin. These compounds may also be 
prepared according to the synthetic methodology disclosed 
herein. For example, the hexamethylhexaethyl derivative of 
9 may be an as-yet uncharacterized byproduct of the reaction 
used to prepare 17. Alternatively, it is contemplated that this 
material may be obtained by controlled reduction of 17 
using hydride reagents and/or controlled hydrogenation. 
EXAMPLE VII 
SYNTHESIS OF SUBSTITUTED RUBYRNS 
AND FURTHER ANALOGUES 
It will also be apparent to one of skill in the art of organic 
chemistry that the two rubyrins presented in FIG. 4 (or their 
reduced congeners as represented by compounds such as 19) 
are not the only ones that can be obtained within the context 
of this synthetic methodology. For example, firstly, the 
inventors contemplate that the choice of bipyrroles for use in 
the second condensation step, as illustrated by the use of 15 
and 16 (to make 17 and 18), may be varied. Secondly, it is 














pyrroles may be employed in the first condensation step to 
produce various analogues of 13 and 14. 
A preliminary example concerns the inventors' use of 
5,5'-diformyl-4,4'-dipropyl-2,2'-bipyrrole as a starting mate 
rial for use in reaction sequences in accordance with the 
present invention. This synthetic process involved reaction 
with compound 12 followed by debenzylation and subse 
quent condensation with compound 16 to yield an analogue 
of compound 10, 8,23-diethyl-4,13,18.27-tetrapropyl-9,22 
dimethylrubyrin, in which four of the 12 possible B-pyrrolic 
positions are unsubstituted by alkyl groups. Satisfactory 
NMR and high resolution mass spectrometric data was 
obtained for this product. 
Accordingly, it is contemplated that a variety of 
approaches may be employed, in accordance with the 
present invention, to prepare systems bearing a wide variety 
of alkyl and/or aryl substituents in the meso and/or B-pyr 
rolic positions. 
For example, meso substituted compounds may be pre 
pared to test the extent to which the presence of different 
groups, such as, for example, 4'-phenyl and/or 2'-phenyl 
donating groups can be made to augment effective nitrogen 
lone pair basicity and/or enhance higher pH phosphate 
transport capability. Extensions to systems bearing two (or 
more) meso substituents are also contemplated within the 
scope of the invention. In any event, it is important to 
appreciate that by adding further meso substituents one will, 
in all likelihood, induce substantial distortions of the mac 
rocycle off planarity. Thus, these syntheses should provide 
compounds that will allow steric effects to be assessed. 
Naturally, it is contemplated that transport and pK tests will 
be conducted to determine the effects of the various substi 
tutions. 
In preliminary work, to date, several phenyl-bearing ruby 
rins have been prepared by a "direct insertion' procedure. 
This procedure (a specific example of which is shown in 
Reaction Scheme A), which is necessarily inefficient, 
involves the condensation of a bis-O-free bipyrrole (e.g., 25) 
with an ol, co-free bis(pyrrolyl)-bipyrrole (e.g., 26) in the 
presence of benzaldehyde or substituted benzaldehyde under 
rubyrin forming conditions, as described herein, to afford 
bisarylrubyrin 27. This inefficiency reflects the fact that in 
addition to the bisarylrubyrin products, one also obtains a 
range of other macrocyclic and non-macrocyclic products. 
Improved syntheses can be envisioned, however, in which 
an O-free, co-protected bipyrrole (e.g., structure 28 in Reac 
tion Scheme B), is co-condensed with an O-free pyrrole 
(e.g., 29) in the presence of an aromatic aldehyde, as in 
Reaction Scheme B. The benzyl ester of the resulting 
pyrrolyl-bipyrrole can then be selectively cleaved under 
standard debenzylation conditions and decarboxylated with 
trifluoroacetic acid to give the O-free pyrrolyl-bipyrrole, 
structure 30. Acid catalyzed condensation of pyrrolyl-bipyr 
role 31 with another molecule of o-free pyrrole 28 in the 
presence of an aromatic aldehyde yields an ethyl ester 
protected diaryl, bis(pyrrolyl)-bipyrrole 32, which can be 
deprotected to form the O, co-free bis(pyrrolyl)-bipyrrole 33. 
Acid catalyzed co-condensation of the tetrapyrrolic frag 
ment 33 with an O, ()-free bipyrrole (e.g., 34) in the presence 
of an aromatic aldehyde, under rubyrin-forming conditions 
such as those described in Example 1, affords a rubyrin with 
each of its four "meso' positions substituted with aryl 







It will, of course, be understood that in syntheses such as 
those exemplified in Reaction Scheme B, substituents in the 
starting compounds, such as those groups represented by R', 
R’, R and R', may be varied as desired. Such groups may 
separately and independently include, for example, H, alkyl, 
aryl, amino, hydroxyl, alkoxy, carboxy, carboxamide, ester, 
amide, sulfonato, hydroxy substituted alkyl, alkoxyl substi 
tuted alkyl, carboxy substituted alkyl, amino substituted 
alkyl, sulfonato substituted alkyl, ester substituted alkyl, 
amide substituted alkyl, substituted aryl, substituted alkyl, 
substituted ester, substituted ether, or substituted amide 
groups. Thus, by using the appropriately substituted starting 
units, a rubyrin product may be produced in which groups 
R-R (as represented by structure 35) may be substituted 
with any of the groups listed above. 
Extensions of known methods can also be straightfor 
wardly conceived that would allow one of skill in the art, in 
light of the present disclosure, to prepare functionalized 
rubyrins bearing one or more non-alkyl substituents in the 3 
positions. As is true for the sapphyrins' the easiest entry 
into such systems involves the preparation of carboxy alkyl 
substituted systems, for example, compounds bearing sub 
stituents such as -(CH), COH, and then further elabo 
rating these to form the corresponding hydroxy alkyl, amino 
alkyl, thiol, sulfanato, ether, amide, ester, or formyl alkyl 
derivatives. 
In addition to the direct conversions described above, it is 
important to appreciate that carboxy alkyl substituted ruby 
rins can also be used as the basis for obtaining other, more 
complex functionalized systems. For instance, as described 
by Král et al., 19927 incorporated herein by reference, for 
the Sapphyrin series, the carboxylic acid group of the car 
boxy alkyl bearing rubyrins can be activated using standard 
reagents (such as, for example, thionyl chloride or DCC) and 
used to prepare either ester- or amide-linked conjugates. 
Again, in analogy to the Sapphyrins, said conjugates could 
include compounds that contain one or more nucleic acid 
base ("nucleobase') or sugar ("saccharide') subunits, as is 
described in detail in the following Examples (Examples 










condense a protected amino alkyl nucleobase, for instance, 
the known material 1-(2-aminoethyl)-4-triphenylmethy 
l)aminol-pyrimidin-2-one', with the activated rubyrin car 
boxylic acid and subsequently effect nucleobase deprotec 
tion. Similarly, one may employ an amino-bearing protected 
Sugar, such as per-O-acetylated glucosamine, and subse 
quent deprotection. In addition, one can use such a conju 
gation approach to prepare complex ethers, esters, or amides 
where the ether, ester, or amide linkages are used to append 
a wide variety of polyfunctional substituted alcohol and/or 
amine fragments on to the rubyrin periphery. 
The requisite carboxy alkyl substituted rubyrins can be 
prepared by several routes. Two of these bear direct analogy 
to the earlier work in the sapphyrin series and thus are 
chosen for highlight in this example. First, in analogy to the 
preparation of 3,12,13,22-tetraethyl-8, 17-bis(carboxyethyl)- 
2,7,18,23-tetramethylsapphyrin', condensation of benzyl 
5-acetoxymethyl-3-methyl-4-(methoxycarbonylethyl)-pyr 
role-2-carboxylate, structure 37, with bipyrrole 36 can be 
used to obtain, following debenzylation, bis(5-carboxy-3- 
(methoxycarbonylethyl)-4-methyl-pyrrol-2-ylmethyl)-2,2'- 
bipyrrole 38b (Reaction Scheme C). This compound, fol 
lowing condensation with bipyrrole 39, under rubyrin 
forming conditions such as those described in Example 1, 
will provide the rubyrin system 40 bearing two carboxy 
alkyl substituents (Reaction Scheme C). In the structures 
represented in scheme C, R, R', R', and R, in the starting 
units and the product, may separately and independently 
include H, alkyl, aryl, amino, hydroxyl, alkoxy, carboxy, 
carboxamide, ester, amide, sulfonato, hydroxy substituted 
alkyl, alkoxyl substituted alkyl, carboxy substituted alkyl, 
amino substituted alkyl, sulfonato substituted alkyl, ester 
substituted alkyl, amide substituted alkyl, substituted aryl, 
substituted alkyl, Substituted ester, substituted ether, or sub 
Stituted amide groups. 
Second, in retrosynthetic analogy to the more recent 
preparation of 3,8,17,22-tetraethyl-12-(carboxyethyl)-2,7, 
13,18,23-pentamethylsapphyrin', benzyl 3,5-dimethyl-4- 
(methoxycarbonylethyl)-pyrrole-2-carboxylate 41 may be 




sponding bipyrrole 44a (3,3'-bis(methoxycarbonylethyl)-5, 
5'-bis(benzyloxycarbonyl)-4,4'-dimethyl-2,2'-bipyrrole) via 
sulfuryl chloride oxidation to acid 42, followed by standard 
iodination (43), and copper bronze mediated Ullman coupling 
44b and Clezy formylation with trifluoroacetic acid (TFA) 
and triethylorthoformate, condensation of the resulting 
bipyrrole 45 (3,3'-bis(methoxycarbonylethyl)-5,5-diformyl 
4,4'-dimethyl-2,2'-bipyrrole) with the tetrapyrrolic fragment 
46 of Reaction Scheme E, under normal rubyrin-forming 10 
conditions such as those described in Example I, will 
provide a rubyrin containing at least two carboxy alkyl 
R1 R O 
. Following standard debenzylation to produce 5 
30 
substituents, at positions 4 and 27, protected as their corre 
sponding methyl esters (structure 47, Reaction Scheme E). 
As with other examples presented herein, R', R', and R of 
structures 46 and 47 may separately and independently 
include H, alkyl, aryl, amino, hydroxyl, alkoxy, carboxy, 
carboxamide, ester, amide, sulfonato, hydroxy substituted 
alkyl, alkoxyl substituted alkyl, carboxy substituted alkyl, 
amino substituted alkyl, sulfonato substituted alkyl, ester 
substituted alkyl, amide substituted alkyl, substituted aryl, 
Substituted alkyl, substituted ester, substituted ether, or sub 
stituted amide groups. 
Scheme C 
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EXAMPLE VIII 
SYNTHESIS OF RUBYRIN-NUCLEOBASE 
CONJUGATES 
It is contemplated that suitable rubyrin-based dibasic 
phosphate chelators may be modified so as to obtain ditopic 
binding systems that display high inherent specificity for a 
given purine or pyrimidine derived nucleotide. This may be 
achieved by adding a synthetic appendage of a nucleobase 
moiety. For example, the known aminobutyl cytosine 
derivative may be employed with an acid-catalyzed detrity 
lation procedure. 
Alternatively, the mode of base attachment may be varied, 
for example, at the level of coupling, protecting group, 
precursors, and the length, nature, and orientation of any 
linking groups. The effects of such variations on yield, 
selective binding, and other properties of the resultant ruby 
rin-based molecule, such as, for example, effective through 
membrane transport capability may then be determined and 
any adjustments made accordingly. For example, the nature 
of R groups may be changed, or 2° amides replaced by 3 
OCS 
In principle, based on preliminary studies which demon 
strated the feasibility of achieving nucleobase "chelation” 
via complementary Watson-Crick type base-pairing interac 
tions, these compounds should display base-selective trans 
port capability. This may be specifically examined by vari 
ous structural, static binding, and dynamic transport 
analyses. In particular, it will be determined whether the 
cytosine-for-guanine selectivity that the inventors observed 
in mixed (i.e. non-covalently linked) systems' holds in the 
case of suitably designed synthetic conjugates. In addition, 
it will be tested whether this same base-pairing approach 
suffices to engender nucleobase selectivity in the case of 
adenine-thymine pairing. 
As an extension of the above analyses, doubly function 
alized systems may be synthesized for use in the selective 












antiviral properties', as well as for the recognition and 
transport of mononucleotides. In the latter case, it is sug 
gested, the possible combination of both Watson-Crick and 
Hoogsteen type base-pairing interactions could confer a 
degree of specificity not available using simpler systems. To 
the extent this proves true, it is possible that the doubly 
functionalized rubyrin system could serve as a viable anti 
viral adjuvant, capable not only of binding and solubilizing 
the phosphate portion of a nucleotide monophosphate, but 
also of effecting its selective through-membrane transport at 
or near physiologic pH. 
The studies carried out in the sapphyrin series stands as an 
allegory of success. For instance, it was found that the 
attachment of a nucleobase to a sapphyrin core greatly 
enhanced the nucleotide recognition selectivity for transport. 
Thus the inventors expect that the functionalization of 
rubyrins, which because of their larger core size and 
increased basicity are inherently much better for anion 
recognition and phosphate anion chelation than sapphyrins, 
will lead to systems of tremendous superiority relative to 
any produced to date. 
Reaction Schemes F through I represent examples of the 
synthesis of rubyrin nucleobase conjugates. The synthetic 
methodology represented in these reaction schemes may be 
straightforwardly adapted for the synthesis of any given 
rubyrin nucleobase compound by employing the desired 
starting materials. Groups R', R. R', and R in Reaction 
Schemes F and G and groups R', R° and R in Reaction 
Schemes H and I, may separately and independently include 
H, alkyl, aryl, amino, hydroxyl, alkoxy, carboxy, carboxa 
mide, ester, amide, sulfonato, hydroxy substituted alkyl, 
alkoxyl substituted alkyl, carboxy substituted alkyl, amino 
substituted alkyl, sulfonato substituted alkyl, ester substi 
tuted alkyl, amide substituted alkyl, Substituted aryl, substi 
tuted alkyl, substituted ester, substituted ether, or substituted 
amide groups. 
The first example of the preparation of a rubyrin nucleo 
base conjugate is shown in Reaction Scheme F. Here, a 
dicarboxy alkyl bearing rubyrin, the 8,23-bis(methoxycar 
bonylethyl)-rubyrin 48 can be saponified to its diacid form 
5,622,945 
37 
49by treatment with a 1:1 mixture of HCl and trifluoroacetic 
acid. DCC coupling of rubyrin diacid 49 with trityl protected 
aminoethyl cytosine 50 in methylene chloride at 0° C. 
followed by deprotection with TFA, as shown in Reaction 
Scheme F, affords the amide linked bis(aminoethyl)cytosine 
rubyrin conjugate 51. 
Similarly, the amide linked bis(aminoethyl)guanosine 
rubyrin conjugate 55 can be prepared by DDC coupling of 
rubyrin diacid 53 with benzoyl-protected aminoethyl gua 
nosie 54 in DMF at 0°C. followed by deprotection with TFA 
as shown in Reaction Scheme G. 
In another example of a dicarboxy alkyl bearing rubyrin, 
the 4.27-bis(methoxycarbonylethyl)-rubyrin 56 (Reaction 














R4 49 R4 
38 
a 1:1 mixture of HCl and trifluoroacetic acid. DCC coupling 
of rubyrin diacid 57 with trityl-protected aminoethyl 
cytosine 58 in methylene chloride at 0° C. followed by 
deprotection with TFA, as shown in Reaction Scheme H, 
affords the amide linked bis(aminoethyl)cytosine rubyrin 
conjugate 59. 
The amide linked bis(aminoethyl)guanosine rubyrin con 
jugate 63 of Reaction Scheme I can be prepared by DDC 
coupling of rubyrin diacid 61 with benzoyl-protected ami 
noethylguanosine 62 in DMF at 0°C. followed by depro 
tection with TFA as shown in Reaction Scheme I. 
Scheme F 
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62 R = COBn 
1) DCC, 0° C. 




SYNTHESIS OF RUBYREN-SACCHARIDE 
CONJUGATES 
Rubyrin derivatives or conjugates including one or more 
Saccharide units may also be prepared according to the 
synthetic methodology described hereinbelow. The sugar 
units (represented originally by structures 65 and 75) in 
Reaction Schemes J through O are intended to represent any 
individual sugar or sugar derivative, such as those set forth 
in Table 2, or polymers thereof, and include modified sugars, 
Such as methyl, amino, and phosphate sugars, and D-, L-, O. 




The synthetic methodology represented in the following 
reaction schemes may be straightforwardly adapted for the 
Synthesis of any rubyrin saccharide compound as desired. 
Groups R', R', R', and R in Reaction Schemes J, L and M, 
and groups R', R° and R in Reaction Schemes K, N and O, 
may separately and independently include H, alkyl, aryl, 
amino, hydroxyl, alkoxy, carboxy, carboxamide, ester, 
amide, Sulfonato, hydroxy substituted alkyl, alkoxyl substi 
tuted alkyl, carboxy substituted alkyl, amino substituted 
alkyl, sulfonato substituted alkyl, ester substituted alkyl, 
amide substituted alkyl, substituted aryl, substituted alkyl, 





For the preparation of amide-linked rubyrin saccharide 
conjugates, such as those represented by structure 66, diacid 
chloride substituted rubyrin 64 (Reaction Scheme J) may be 
prepared by treating its respective diacid rubyrin, formed as 
shown in Reaction Scheme J, with thionyl chloride. The 
rubyrin diacid chloride 64thus prepared can be coupled with 
the acetoxy protected HBr salt of amino saccharide 65 in 
methylene chloride and pyridine, and deprotected with KOH 
in methanol as in Reaction Scheme J. 
In the same fashion, the 4,17-bis(acid chloride)rubyrin 67 
(Reaction Scheme K) can be prepared by treating its respec 
tive diacid rubyrin, formed as shown in Reaction Scheme H, 
with thionyl chloride. The amide-linked bis(saccharide) 
rubyrin 68b may be prepared by coupling rubyrin diacid 
chloride 67 with the acetoxy protected HBr salt of amino 
Saccharide 65 in methylene chloride and pyridine, followed 
by deprotection with KOH in methanol as illustrated in 
Reaction Scheme K. 
To prepare ether-linked bis(saccharide)rubyrin conju 
gates, the dihydroxy functionalized rubyrins, such as those 







prepared. For example, reduction of the methyl esters of 
tetracycle 69 with borane-THF to the corresponding alco 
hols followed by protection with acetic anhydride provides 
the acetoxy-protected diol 71a. Standard debenzylation to 
afford 71b followed by condensation with diformyl bipyr 
role 72, under rubyrin-forming conditions such as those 
described in Example I, provides the acetoxy-protected 
dihydroxy rubyrin 73a. Deprotection of the hydroxyl groups 
can be achieved by treatment with HCl in methanol to afford 
dihydroxyrubyrin 73b. 
Dihydroxyrubyrins, formed as described above (Reaction 
Scheme L), can be coupled with acetoxy- and/or benzoyl 
protected bromo-substituted saccharide units, such as struc 
ture 75 (Reaction Scheme M), in methylene chloride with 
silver triflate and barium carbonate. This results in the 
production of acetoxy- and/or benzoyl-protected bis(saccha 
ride)rubyrin conjugates such as 76a in Reaction Scheme M. 
Treatment of the acetoxy and/or benzoyl protected bis(sac 
charide)rubyrin 76a with KOH in methanol yields the cor 
responding deprotected bis(saccharide)rubyrin conjugate 
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75 R = Ac, COBn 
AgCF3SO3, BaCO3 










76a R = Ac, CO2Bn 2 KOHIMeOH 
16b Rs. H 
To prepare an ether linked bis(saccharide)rubyrin conju 
gate with the ether linkages in the 4 and 17 positions on the 
rubyrin periphery, the appropriate acetoxy-protected 
diformyl bipyrrole can be prepared as shown in Reaction 
Scheme N. Reduction of the methyl esters of bipyrrole 77 
with borane-THF to the corresponding alcohols followed by 
protection with acetic anhydride provides the acetoxy-pro 
tected diol 79a. Standard debenzylation, to afford diacid 79b, 
followed by Clezy formylation with TFA and triethylortho 
formate yields the acetoxy-protected bipyrrole 80. Conden 
sation of bipyrrole 80 with diacid 81, under rubyrin-forming 
conditions, provides the acetoxy-protected dihydroxy ruby 
rin 82a. Deprotection of the hydroxyl groups can be 
55 
60 
achieved by treatment with HCl in methanol to afford 
dihydroxyrubyrin 82b. 
The dihydroxyrubyrin thus formed can be coupled with 
acetoxy- and/or benzoyl-protected bromo-substituted sac 
charide units, such as structure 75 (Reaction Scheme O), in 
methylene chloride with silver trifiate and barium carbonate 
to afford the acetoxy- and/or benzoyl-protected bis(saccha 
ride)rubyrin conjugate 84a, as shown in Reaction Scheme O. 
Treatment of the acetoxy and/or benzoyl protected bis(sac 
charide)rubyrin 84a with KOH in methanol yields the cor 
responding deprotected bis(saccharide)rubyrin conjugate 













SYNTHESIS OF RUBYRIN ANALOGUES 
EMPLOYING HETEROATOMS 
In addition to the above rather direct extensions, the 
skilled artisan will appreciate that either bifuran and/or 
bithiophene subunits can be used in place of bipyrroles 11, 
15, or 16 (FIG. 4). Using a subunit substitution, which will 
be known to those of skill in the art in light of the present 
disclosure, will enable the preparation of heteroatom ruby 
rin-type compounds. These include, for example, those 
depicted by generalized structures 20-24 in FIG. 6, and 
structures 87,92, 99 and 104 of Reaction Schemes P through 
S, respectively. 
In light of the present disclosure and the recent work in 
the sapphyrin area, for example, Sessler et al., 199279, 
incorporated herein by reference, one of skill in the art 
would be able to prepare compounds of the general type 
shown in FIG. 6, and further exemplified in Reaction 
Scheme P through Reaction Scheme S. In particular, it is 
important to appreciate that 5,5'-diformyl-2,2'-bifuran and 
5,5'-diformyl-2,2-bithiophene are now readily available 
materials''. Simple condensation of these materials, in a 
normal rubyrin-forming manner, with a tetrapyrrolic frag 
ment such as compound 14 of FIG. 4 would be expected, 
therefore, to produce rubyrin analogues of general class 22 
and 23, in which two of the normal six pyrrolic nitrogens are 
replaced by sulfur or oxygen, respectively. 
Reaction Schemes P through S represent examples of the 
synthesis of rubyrin analogues employing heteroatoms. The 
starting materials for use in the syntheses represented in 
these reaction schemes, and hence the resultant products, 
may include various substituents, such as, for example, H, 








ester, amide, sulfonato, hydroxy substituted alkyl, alkoxyl 
substituted alkyl, carboxy substituted alkyl, amino substi 
tuted alkyl, sulfonato substituted alkyl, ester substituted 
alkyl, amide substituted alkyl, substituted aryl, substituted 
alkyl, substituted ester, substituted ether, or substituted 
amide groups. 
A synthetic scheme depicting the synthesis of such a 
rubyrin in which two of the normal six nitrogen heteroatoms 
are replaced by oxygen or sulfur is shown in Reaction 
Scheme P. The diacid tetrapyrrolic fragment 85 can be 
condensed with the readily available diformyl bifuran or 
diformyl bithiophene 86 under rubyrin-forming conditions, 
such as those described in Example I, to afford rubyrin 
analogue 87, where X can be either O or S. 
Rubyrin analogues in which two different pyrrolic nitro 
gens have been replaced by the heteroatoms oxygen or 
sulphur may also be prepared, for example, as shown in 
Reaction Scheme Q. Condensation of bipyrrole 88 with the 
acetoxy-activated furan or thiophene 89 to produce the 
tetracycle 90, followed by condensation with bipyrrole 91, 
under rubyrin forming conditions such as those described in 
Example I, produces the 28t-electron rubyrin analogue 92, 
where X can be either oxygen or sulfur. 
Reduction of bifuran or bithiophene fragments to the 
corresponding 5,5'-bisacetoxymethyl derivatives will pro 
vide precursors that, in analogy to the recent work in the 
heterosapphyrin area (Sessler et al., 1992' incorporated 
herein by reference), will allow, following condensation 
with benzyl 3-ethyl-4-methyl-pyrrole-2-carboxylate and 
subsequent hydrogenolysis (to remove the benzyl groups), 
the preparation of analogues of 14 in which the central 
tetraalkyl bipyrrole is replaced by either a bifuran or 
bithiophene moiety. Said analogues, following condensation 
with the appropriate diformyl-substituted bifuran or 




analogues of generalized structure 20, 21, and 24, with the 
exact class of compound prepared depending on whether a 
bifuran (or bithiophene) containing tetracycle is condensed 
with a bifuran or bithiophene bicycle, as would be appreci 
68 
sis of 97a with H and Pd/C affords diacid 97b, which can 
be condensed with the bicyclic fragment 98 (where Y=O or 
Y=S), under rubyrin forming conditions, to produce rubyrin 
analogue 99, where X and Y can separately and indepen 
ated by one of skill in the art. 5 dently be oxygen or sulfur. 
A synthetic scheme depicting the synthesis of a rubyrin Rubyrin analogues in which all six of the nitrogen atoms 
analogue with four of the nitrogen heteroatoms replaced by have been replaced by oxygen or sulfur heteroatoms may 
four oxygen or four sulfur atoms, or a combination of two also be Synthesized, for example, as shown in Reaction 
oxygen and two Sulphur atoms, is shown in Reaction Scheme S. Condensation of the readily available bifuran or 
Scheme R. The readily available compound 93, where X can 10 bithiphene 100 with the readily available acetoxy-activated 
be either O or S, can be reduced to the diol 94 by treatment furan or thiophene 101 affords the tetracycle 102. Condens 
with lithium aluminum hydride and subsequently acetoxy- ing molecule 102 with a diformyl bifuran or diformyl 
protected with acetic anhydride to provide compound 95. bithiophene 103, under rubyrin forming conditions such as 
Acid catalyzed condensation of bifuran or bithiophene 95 those described in Example I, will give the 28t-electron 
with benzyl 3-ethyl-4-methyl-pyrrole-2-carboxylate in iso- 15 macrocycle 104 where X, Y, and Z may be any combination 

















03 Z= O or S 
With such heteroatomic compounds, one may determine 
how changes in size, shape, and macrocycle denticity (the 
number of "coordinating' NH groups) affect monophos 
phatc binding, and also define the basic structural param 
eters associated with efficient through-membrane transport 
of GMP-like species. Developing this theme will allow a 
determination of how these same changes in core structure 
are reflected in terms of an ability (or lack thereof) to bind 
and transport other phosphorylated species, including such 
important species as cyclic nucleotide monophosphates (e.g. 
c-AMP), diphosphates (e.g. GDP), and triphosphates (e.g. 
ATP). Also, the extent to which these systems, and/or their 
monoprotonated derivatives, can act as receptors/carriers for 
various halides, including, of course, chloride anion may be 
investigated. 
Furthermore, it is again contemplated that some or all of 
the 3-pyrrolic positions in these systems may be substituted 
with alkyl or functionalized alkyl substituents. Thus, a wide 
variety of structures are conceived within the context of the 
basic synthetic methodology presented in FIG. 4. 
EXAMPLE XI 
RUBYRIN AND RUBYRIN ANALOGUES AS 
CHELATING RECEPTORS 
To date, labile bis-zinc derivatives of 10a and 10b have 
been made. However, it is envisioned that the diprotonated 
rubyrin systems will act as effective receptors for a variety 
of anions, as is true for sapphyrin when protonated', and 
possibly other cationic expanded porphyrins''. For 
instance, preliminary spectroscopic studies with system 10a 
indicate that diprotonated rubyrin can bind both fluoride and 
phosphate anions in a strong and non-labile manner. 
Furthermore, the monoprotonated form of rubyrin 10a has 
been shown to act as an effective carrier for the through 
membrane transport of guanosine-5'-monophosphate in 
Pressman type model system. In light of these results, 
protonated rubyrins are proposed to be of use in a variety of 
molecular recognition applications, that are not within the 
purview of normal tetrapyrrolic porphyrin chemistry. 
Once a range of rubyrin analogues have been generated, 
for example, as described herein in the foregoing detailed 
examples, the thermodynamics and kinetics of anion binding 
under a range of conditions and with an array of different 
anions may be determined. The structure and function of the 
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such that they bind either phosphate-bearing nucleotides, or 
chloride ions, with high affinity and selectivity at neutral pH. 
As a complement to structural studies, quantitative analy 
ses may also be conducted. For example, the relevant pK. 
values for various rubyrins may be determined by employ 
ing the methods previously used to determine the pK. 
values for sapphyrin and anthraphyrin'". One should 
beware of possible “artifacts” arising from anion chelation, 
which can be avoided by using non-chelating buffers and 
solvents. Such initial studies should be followed by ones in 
which the various pK values are recorded in different 
solvents and in the presence of different anions such as 
hydrosulfate, bicarbonate, azide, cyanide, fluoride, bromide, 
and iodide, that are of biological relevance. Other qualitative 
tests (e.g. UV/vis, FABMS) may also be used to reconfirm 
that rubyrins do not form complexes under physiological 
conditions with Na', K", Ca", or other bio-cations. The 
reason for these latter studies is that such cation complex 
formation could preclude efficient anion binding and trans 
port. 
Once pK values are recorded, a second set of quantita 
tive analyses may be performed to determine the actual 
affinity constants for each and every relevant receptor-to 
anionic interaction. Thus, for instance, K, for. HRub’ 
GMP formation in a variety of solvent systems may be 
measured in a similar manner to that for the hydrohalide 
salts of sapphyrin and anthraphyrin'". Standard methods as 
quantitative UV/vis titrations and concentration dependent 
NMR chemical shift analyses may be used, along with more 
sophisticated techniques such as those involving static and 
time-resolved fluorescence. The inventors have determined 
that the latter methods offer considerable advantages and are 
particularly useful for measuring high affinity constants (i.e. 
those in the K210 M range). These fluorescence-based 
methods require highly colored materials with good singlet 
state emission characteristics, but these criteria are clearly 
met by the rubyrins. 
Quantitative kinetic studies may also be carried out and 
used to determine whether the rate limiting step in GMP (or 
chloride) transport involves initial receptor-anion complex 
formation, through-membrane carrier-complex diffusion, 
product release, and/or rate of carrier back-diffusion. On 
and off-rates for complex formation may be measured, for 
example, by dynamic NMR, UV/vis, or time-resolved fluo 
rescence, in, e.g., simple water-saturated dichloromethane 
solutions. More precise analyses of receptor-mediated trans 
port may also be made, again with a mind to determining 




The U-tube model system may be employed, and when 
appropriate, more Sophisticated membrane analogues such 
as mixed phosphatidylcholine-cholesterol liposomes can be 
used 8. 
For the latter studies, it may prove most convenient to 
prepare nucleotide or halide encapsulating liposomes and 
then determine the kinetics of anion extrusion as a function 
of carrier concentration and/or external solution pH. Here 
again, either UV/vis or time-resolved fluorescence analyses 
may be used. Here, it might prove necessary to add a specific 
fluorophore, such as 6-methoxy-N-(3-sulphopropyl)guino 
linium (a halide selective reagent) to the outside phase so as 
to be able to detect small quantities of the anionic “escap 
CCS. 
EXAMPLE XII 
RUBYRIN AND ANALOGUES AS CELLULAR 
ANION TRANSPORTERS 
In preliminary transport screening studies, using a H2O 
CHCl2-H2O Pressman-type''' U-tube model system, 
rubyrin was found to be capable of effecting through 
membrane transport of GMP and other nucleotides at near 
neutral pH (i.e. in the pH 6.0 to 6.5 regime). In contrast, 
Sapphyrin was completely ineffective, and pentaphyrin 
mediated only very slow GMP transport, which was further, 
and unfortunately, Subject to inhibition by chloride anions. 
Thus, it is clear that for any conceivable phosphate chelation 
or recognition applications the rubyrins will emerge as being 
vastly superior to either the pentaphrins or sapphyrins. 
The effective transport by rubyrin, a larger, more basic 
system, may derive from lower in-core NH'-to-NH repul 
sions. In any event, these properties make rubyrin an ideal 
candidate for use in the delivery of phosphorylated com 
pounds such as antivirals. The ability of rubyrin to effect 
nucleotide transport in a manner that is free of any chloride 
(or other halide) anion inhibition (even though this same 
material binds chloride anion quite effectively at very low 
pH and in the solid state) is particularly important. 
Furthermore, the inventors determined that transport 
effected by this latter rubyrin carrier could be made some 
what nucleobase selective by adding the appropriate 
complementary TIPS derivative to the organic membrane 
phase. For example, in the presence of C-Tips (triisopropyl 
silyl-protected cytidine), the rate of rubyrin-mediated GMP 
transport was observed to be substantially enhanced. Results 
from such exploratory studies thus support not only the 
suggestion that it should be possible to effect base-specific 
phosphate (or phosphonate) entity transport under physi 
ological conditions, but also the contention that, by synthetic 
"selection” or "fine tuning” it should be possible to design 
rubyrin anion receptors that are selective for either phos 
phate-derived antivirals, or chloride anion, or both. 
In further studies, those kinetic and thermodynamic fac 
tors that militate both for and against rapid, selective trans 
port of phosphorylated nucleotides and nucleotide analogues 
can be precisely determined. Both the use of simple U-tube 
and more elaborate liposomal test systems is contemplated. 
EXAMPLE XIII 
USE OF RUBYRIN AND ANALOGUES AS 
THERAPEUTICAGENTS 
Rubyrin compounds of the present invention are contem 
plated to be of use as anion transporters in various embodi 














contemplated for use as delivery agents for antiviral com 
pounds and may thus be employed to combat a variety of 
diseases including AIDS, herpes, hepatitis and measles. 
Rubyrin compounds optimized for chloride transport are 
also contemplated for use in the treatment of cystic fibrosis. 
In developing the rubyrin compounds of the present 
invention for therapeutic use as anti-viral transporters, in 
vitro tests will first be conducted. These will follow proto 
cols similar to those used earlier to screen the photodynamic 
antiviral activity of sapphyrin and several other expanded 
porphyrins'. In brief, a monolayer of Vero cells will be 
infected with HSV-1, coated with an overlay culture 
medium, and then exposed to various relative and absolute 
concentrations of both putative carrier and known active 
antiviral. Then, following incubation at 37° C., adjuvant 
efficacy will be determined by counting the number of 
plaque forming units (PFU) obtained in the presence and 
absence of a given carrier. 
Following such in vitro tests, the activity of promising 
rubyrin receptors will be followed-up, for example, in 
anti-HIV screens, and then in in vivo animal studies. These 
Studies will be conducted according to the standard practice 
for Such animal trials, the execution of which will be known 
to those of skill in the art. 
During the animal trial stage, the rubyrin compounds, 
whether used in antiviral delivery, or for chloride transport 
in cystic fibrosis treatment, may be modified further if 
required. They might, for instance, be modified to overcome 
poor water solubility or susceptibility to in vivo degradation. 
Alternatively, if such problems occur, the rubyrins could be 
enveloped within a bio-compatible liposome (made, e.g. 
from Cremophor)' and then administered intravenously. 
Such an approach has previously resulted in good in vivo 
murine adenocarcinoma photodynamic tumor killing with a 
water-insoluble texaphyrin-type expanded porphyrin'. The 
"Trojan Horse' method' could also be employed to deliver 
the rubyrin antiviral carrier in vivo to the desired locus of 
biological activity. Here, the idea would be to use non 
infectious viral membrane material to produce liposomes 
and then use these in turn as transport vehicles to get the 
putative carrier to the site of cellular infectivity. 
Naturally, toxicity studies will also be carried out at this 
stage. The methods for determining both acute and chronic 
toxicity will be known to those of skill in the art. Available 
evidence indicates that rubyrins, like sapphyrins, will be 
relatively nontoxic. Toxicity can be investigated in relation 
to Solubility, net charge at physiologic pH, and changes in 
appended B-pyrrolic and/or meso substituents. 
Furthermore, the phosphate-binding rubyrin compounds 
of the present invention may act as receptors and transport 
ers for other biologically important molecules with negative 
charges, particularly, polynucleic acids such as DNA, RNA 
and oligonucleotides. Another dimension to the invention, 
therefore, concerns the possibility of using rubyrins in the 
transport of DNA molecules, such as antisense DNA con 
Structs, into cells for use in so-called gene therapy programs. 
Normal cellular uptake of negatively-charged DNA is 
known to be limited. Current in vitro methods rely on severe 
cellular modifications which often cause excessive cell 
damage', and as a result, are not viable in vivo. The 
"coating” of nucleic acid phosphate groups with rubyrins, 
thus rendering them suitable for diffusional uptake in vivo, 
is therefore very attractive and even has implications for 
chromosomal gene therapy. 
While the compositions and methods of this invention 
have been described in terms of preferred embodiments, it 
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will be apparent to those of skill in the art that variations may 
be applied to the composition, methods and in the steps or 
in the sequence of steps of the method described herein 
without departing from the concept, spirit and scope of the 
invention. More specifically, it will be apparent that certain 
agents which are both chemically and physiologically 
related may be substituted for the agents described herein 
while the same or similar results would be achieved. All 
such similar substitutes and modifications apparent to those 
skilled in the art are deemed to be within the spirit, scope and 
concept of the invention as defined by the appended claims. 
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What is claimed is: 
1. A macrocycle with one of the following structures: 
5,622,945 
STRUCTURE I 
R2 R1 R R2 STRUCTURE II 





R5 R6 R6 R5 
wherein: 
A and A are nitrogen, oxygen or sulphur; and the 
Substituents R, R2, R, R R5, and R and X1, X2, X, 
and X are independently in each occurrence H, alkyl, 
aryl, amino, hydroxyl, alkoxy, carboxy, carboxamide, 
ester, amide, Sulfonate, hydroxy substituted alkyl, 
alkoxyl substituted alkyl, carboxy substituted alkyl, 
ester substituted alkyl, amide substituted alkyl, amino 
Substituted aryl, ester substituted aryl, ether substituted 
aryl, alkoxy substituted aryl, carboxy substituted aryl, 
amide substituted aryl, thio Substituted ester, phospho 
Substituted ester, amino substituted ester, or are of the 
formula (CH)-A-(CH2)-B, wherein A is CH, 
O, S, NH, or NR, wherein R is any of the groups 
listed above, n and m are integers <10 or zero, and B 
includes a nucleobase or saccharide moiety. 
2. The macrocycle of claim 1, wherein the macrocycle is 
either singly or doubly protonated. 
3. The macrocycle of claim 2, wherein the macrocycle has 
a structure in accordance with structure I. 
4. The macrocycle of claim 2, wherein the macrocycle has 














5. The macrocycle of claim 2, wherein the macrocycle has 
a structure in accordance with structure III. 
6. The macrocycle of claim 5, wherein the macrocycle is 
either singly, doubly, triply, or four-fold protonated. 
7. The macrocycle of claim 1, wherein A and A are 
nitrogen. 
8. The macrocycle of claim 1, wherein A and A are 
OXygen. 
9. The macrocycle of claim 1, wherein A and A are 
sulphur. 
10. The macrocycle of claim 1, wherein either A or A is 
nitrogen and the other is oxygen. 
11. The macrocycle of claim 1, wherein either A or A is 
nitrogen and the other is sulphur. 
12. The macrocycle of claim 1, wherein either A or A is 
oxygen and the other is sulphur. 
13. The macrocycle of claim 1, wherein B is a nucleobase 
and the nucleobase is a purine or pyrimidine, or an analog 
thereof. 
14. The macrocycle of claim 13, wherein the purine or 
pyrimidine or analog thereof comprises an antimetabolic, 
antienzymatic, antitumor, anticellular, antiproliferative or 
antiviral purine or pyrimidine analog selected from Table I. 
15. The macrocycle of claim 14, wherein the purine or 
pyrimidine analog comprises an antiviral, antimetabolic or 
antienzymatic compound. 
16. The macrocycle of claim 14, wherein the purine or 
pyrimidine analog comprises an antitumor compound. 
17. The macrocycle of claim 1, wherein B is a nucleobase 
and the nucleobase is cytosine, guanine, thymidine, adenine, 
uridine or inosine. 
18. The macrocycle of claim 1, wherein B is a nucleobase 
and the nucleobase is selected from Table I. 
19. The macrocycle of claim 1, wherein B is a nucleobase 
and the nucleobase includes a protecting group on an amino 
group of the nucleobase, wherein the protecting group is 
9-fluorenylmethylcarbonyl, benzyloxycarbonyl, 4-methox 
yphenacyclocarbonyl, t-butyloxycarbonyl, 1-adamantyloxy 
carbonyl, benzoyl, N-triphenylmethyl, N-di-(4-methoxyphe 
nyl)phenylmethyl. 
20. The macrocycle of claim 1, wherein B is a nucleobase 
and the nucleobase is an antimetabolite. 
21. The macrocycle of claim 20, wherein the antimetabo 
lite is FU, AraC, AZT, ddI, xylo-GMP, Ara-AMP, PFA or 
LOMDP. 
22. The macrocycle of claim 1, further defined as having 
a structure of FIG. 10 and wherein the macrocycle is 
mono-substituted with nucleobase. 
23. The macrocycle of claim 1, further defined as having 
a structure of FIG. 10, wherein the macrocycle is disubsti 
tuted with nucleobase. 
24. The macrocycle of claim 1, wherein B is a saccharide 
moiety. 
25. The macrocycle of claim 24, wherein the saccharide 
moiety is a Sugar, Sugar derivative, or polysaccharide. 
26. The macrocycle of claim 25, wherein the sugar or 
Sugar derivative has a phosphate, methyl or amino group. 
27. The macrocycle of claim 24, wherein the saccharide 
moiety is ribose, arabinose, xylose, lyxose, allose, altrose, 
glucose, mannose, gulose, idose, galactose, talose, ribulose, 
xylulose, psicose, fructose, Sorbose, tagatose, fucose, meth 
ylglucoside, glucose-6-phosphate, N-acetylgalactosamine, 
N-acetylglucosamine, or sialic acid. 
28. The macrocycle of claim 24, wherein the saccharide 





29. A macrocycle with one of the following structures: 
STRUCTURE I 
STRUCTURE I 
















A and A2 are nitrogen, oxygen or sulphur, and the 
Substituents R, R2, Ra, Ra, R5, and R and X1,X2, X, 
and X are independently in each occurrence H, alkyl, 
aryl, amino, hydroxyl, alkoxy, carboxy, carboxamide, 
ester, amide, sulfonate, hydroxy substituted alkyl, 
alkoxyl Substituted alkyl, carboxy Substituted alkyl, 
ester substituted alkyl, amide substituted alkyl, amino 
substituted aryl, ester substituted aryl, ether substituted 
aryl, alkoxy substituted aryl, carboxy substituted aryl, 
amide substituted aryl, thio substituted ester, phospho 
substituted ester, amino substituted ester, or are of the 
formula (CH), -A-(CH2)-B, wherein A is CH2, 
O, S, NH, or NR, wherein R is any of the groups 
listed above, n and m are integers <10 or zero, and B 
includes a metal chelating group, alkylating agent, 
steroid, steroid derivative, amino acid, peptide, 
polypeptide, a rubyrin molecule, rubyrin derivatives, or 
polymeric rubyrin, Sapphyrin or texaphyrin or poly 
mers or derivatives thereof, polymer matrix or solid 
Support. 
30. The macrocycle of claim 29, wherein B is a metal 
chelating agent. 
31. The macrocycle of claim 29, wherein B is asteroid or 
steroid derivative. 
32. The macrocycle of claim 29, wherein B is an amino 
acid. 
33. The macrocycle of claim 29, wherein B is a peptide or 
polypeptide. 
34. The macrocycle of claim 29, wherein B is a rubyrin 
molecule, rubyrin derivatives or polymeric rubyrin. 
35. The macrocycle of claim 29, wherein B is a sapphyrin 
or texaphyrin or polymers or derivatives thereof. 
36. The macrocycle of claim 29, wherein B is a polymer 
matrix or solid support. 
  
